This O
is O
the O
first O
description O
of O
an O
HIV B
- I
2 I
enhancer I
element I
which O
displays O
such O
monocyte O
specificity O
, O
and O
no O
comparable O
enhancer B
element I
has O
been O
clearly O
defined O
for O
HIV O
- O
1 O
. O

While O
a O
nuclear B
factor I
( O
s O
) O
from O
both O
peripheral O
blood O
monocytes O
and O
T O
cells O
binds O
the O
peri B
- I
kappa I
B I
site I
, O
electrophoretic O
mobility O
shift O
assays O
suggest O
that O
either O
a O
different O
protein O
binds O
to O
this O
site O
in O
monocytes O
versus O
T O
cells O
or O
that O
the O
protein O
recognizing O
this O
enhancer B
element I
undergoes O
differential O
modification O
in O
monocytes O
and O
T O
cells O
, O
thus O
supporting O
the O
transfection O
data O
. O

Understanding O
the O
monocyte O
- O
specific O
function O
of O
the O
peri B
- I
kappa I
B I
factor I
may O
ultimately O
provide O
insight O
into O
the O
different O
role O
monocytes O
and O
T O
cells O
play O
in O
HIV O
pathogenesis O
. O

To O
address O
potential O
mechanisms O
by O
which O
estrogens O
suppress O
erythropoiesis O
, O
we O
have O
examined O
their O
effects O
on O
GATA B
- I
1 I
, O
an O
erythroid B
transcription I
factor I
that O
participates O
in O
the O
regulation O
of O
the O
majority O
of O
erythroid B
cell I
- I
specific I
genes I
and O
is O
necessary O
for O
full O
maturation O
of O
erythrocytes O
. O

The O
transcriptional O
response O
of O
the O
IL B
- I
2R I
alpha I
gene I
to O
stimulation O
by O
IL B
- I
1 I
+ O
IL B
- I
2 I
is O
biphasic O
. O

It O
also O
primes O
cells O
to O
become O
IL B
- I
2 I
responsive O
and O
thereby O
prepares O
the O
second O
phase O
, O
in O
which O
IL B
- I
2 I
induces O
a O
100 O
- O
fold O
further O
increase O
in O
IL B
- I
2R I
alpha I
transcripts I
. O

Transient O
transfection O
experiments O
show O
that O
several O
elements O
in O
the O
promoter B
- I
proximal I
region I
of O
the O
IL B
- I
2R I
alpha I
gene I
contribute O
to O
IL B
- I
1 I
responsiveness O
, O
most O
importantly O
an O
NF B
- I
kappa I
B I
site I
conserved O
in O
the O
human B
and I
mouse I
gene I
. O

Transient O
transfection O
experiments O
show O
that O
several O
elements O
in O
the O
promoter B
- I
proximal I
region I
of O
the O
IL B
- I
2R I
alpha I
gene I
contribute O
to O
IL B
- I
1 I
responsiveness O
, O
most O
importantly O
an O
NF B
- I
kappa I
B I
site I
conserved O
in O
the O
human B
and I
mouse I
gene I
. O

To O
investigate O
the O
signaling O
pathways O
involved O
in O
the O
gene O
induction O
, O
five O
inhibitors O
, O
cyclosporin O
A O
( O
CsA O
) O
, O
transforming B
growth I
factor I
- I
beta I
, O
cycloheximide O
, O
genistein O
, O
and O
staurosporine O
A O
, O
were O
used O
in O
analyzing O
the O
effects O
of O
IL B
- I
2 I
and O
IL B
- I
12 I
on O
NK3 O
. O
3 O
cells O
. O

We O
examined O
alpha B
A1 I
( O
an O
alpha B
A I
- I
gene I
product I
) O
and O
alpha B
B1 I
and O
alpha B
B2 I
( O
two O
alpha B
B I
- I
encoded I
isomers I
) O
for O
their O
effects O
on O
the O
GM B
- I
CSF I
promoter I
. O

We O
examined O
alpha B
A1 I
( O
an O
alpha B
A I
- I
gene I
product I
) O
and O
alpha B
B1 I
and O
alpha B
B2 I
( O
two O
alpha B
B I
- I
encoded I
isomers I
) O
for O
their O
effects O
on O
the O
GM B
- I
CSF I
promoter I
. O

The O
increased O
transcriptional O
rate O
correlated O
with O
a O
marked O
increase O
in O
nuclear B
factor I
- I
kappa I
B I
activity O
in O
these O
cells O
as O
determined O
by O
electrophoretic O
mobility O
shift O
assay O
using O
a O
consensus B
NF I
- I
kappa I
B I
oligonucleotide I
. O

Control O
of O
I B
kappa I
B I
- I
alpha I
proteolysis O
by O
site O
- O
specific O
, O
signal O
- O
induced O
phosphorylation O
. O

When O
either O
serine O
- O
32 O
or O
serine O
- O
36 O
of O
I B
kappa I
B I
- I
alpha I
was O
mutated O
, O
the O
protein O
did O
not O
undergo O
signal O
- O
induced O
phosphorylation O
or O
degradation O
, O
and O
NF B
- I
kappa I
B I
could O
not O
be O
activated O
. O

Double B
- I
stranded I
GIRE I
sequence I
, O
but O
not O
a O
scrambled B
sequence I
, O
was O
specifically O
bound O
by O
nuclear B
proteins I
from O
IFN O
- O
gamma O
treated O
U937 O
cells O
. O

The O
Fc B
gamma I
RIC I
GIRE I
is O
homologous O
to O
the O
IFN B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
of O
the O
guanylate B
binding I
protein I
and O
to O
X B
box I
elements I
of O
class B
II I
MHC I
genes I
. O

Murine B
macrophage I
inflammatory I
protein I
1 I
alpha I
( O
MIP B
- I
1 I
alpha I
) O
and O
its O
human B
equivalent I
( O
GOS19 B
, O
LD78 B
, O
or O
AT464 B
) O
are O
members O
of O
the O
- B
C I
- I
C I
family I
of O
low B
- I
molecular I
- I
weight I
chemokines I
. O

In O
transfection O
assays O
, O
the O
human B
GM I
- I
CSF I
element I
has O
a O
strong O
positive O
effect O
on O
the O
expression O
of O
a O
reporter B
gene I
by O
the O
human O
T O
cell O
line O
Jurkat O
J6 O
upon O
stimulation O
. O

Aspirin O
inhibits O
nuclear B
factor I
- I
kappa I
B I
mobilization O
and O
monocyte O
adhesion O
in O
stimulated O
human O
endothelial O
cells O
. O

The O
5 B
' I
flanking I
region I
of O
the O
human B
alpha I
- I
globin I
gene I
is O
highly O
G O
+ O
C O
rich O
and O
contains O
multiple O
copies O
of O
the O
consensus B
sequence I
for O
the O
Sp1 B
binding I
site I
. O

Formation O
of O
the O
NFAT B
- I
1 I
transcriptional I
complex I
on O
the O
IL B
- I
2 I
promoter I
is O
essential O
for O
IL B
- I
2 I
transcription O
. O

We O
transfected O
promoter B
- I
luciferase I
reporter I
plasmids I
into O
THP O
- O
1 O
cells O
to O
define O
sequences O
that O
mediate O
transcriptional O
control O
during O
monocyte O
differentiation O
. O

These O
results O
imply O
that O
at O
least O
three O
signals O
are O
required O
to O
activate O
the O
GM B
- I
CSF I
proximal I
promoter I
, O
and O
that O
the O
signals O
impinge O
on O
distinct O
transcription B
factors I
that O
bind O
to O
the O
hCLEO B
and I
NF I
- I
kappa I
B I
regions I
of O
the O
promoter B
. O

Levels O
of O
the O
octamer O
, O
NF B
- I
kappa I
B I
( O
p50 B
- I
p65 I
heterodimer I
) O
, O
and O
AP B
- I
1 I
transcriptional I
factors I
are O
constitutively O
elevated O
in O
freshly O
isolated O
Ipr O
CD4 O
- O
8 O
- O
T O
cells O
, O
consistent O
with O
the O
activated O
phenotype O
of O
these O
cells O
. O

Type B
II I
major I
histocompatibility I
complex I
combined O
immune O
deficiency O
( O
type O
II O
MHC B
CID O
or O
bare O
lymphocyte O
syndrome O
) O
is O
a O
congenital O
immunodeficiency O
disease O
characterized O
by O
absent O
MHC B
class I
II I
expression O
. O

The O
transcription O
activation O
function O
is O
provided O
by O
the O
N B
- I
terminal I
acidic I
domain I
( O
amino B
acids I
26 I
- I
137 I
) O
, O
which O
is O
experimentally O
exchangeable O
with O
a O
heterologous B
viral I
transcription I
- I
activating I
domain I
. O

The O
transcription O
activation O
function O
is O
provided O
by O
the O
N B
- I
terminal I
acidic I
domain I
( O
amino B
acids I
26 I
- I
137 I
) O
, O
which O
is O
experimentally O
exchangeable O
with O
a O
heterologous B
viral I
transcription I
- I
activating I
domain I
. O

Transient O
transfections O
using O
reporter B
constructs I
with O
multiples O
of O
transcription B
factor I
binding I
sites I
from O
the O
IL B
- I
2 I
promoter I
[ O
distal B
nuclear I
factor I
( I
NF I
) I
- I
AT I
, O
proximal B
NF I
- I
AT I
, O
AP B
- I
1 I
/ I
Octamer I
( O
UPS B
) O
or O
NF B
- I
chi I
B I
( O
TCEd B
) O
sites O
] O
were O
performed O
. O

In O
EBV O
- O
transformed O
B O
clones O
, O
the O
chi B
B I
site I
exerted O
the O
strongest O
inducible O
activity O
; O
the O
NF B
- I
AT I
binding I
sites I
showed O
either O
no O
or O
only O
weak O
activity O
compared O
to O
Jurkat O
T O
cells O
. O

Latent B
membrane I
protein I
- I
1 I
induces O
cyclin B
D2 I
expression O
, O
pRb B
hyperphosphorylation O
, O
and O
loss O
of O
TGF B
- I
beta I
1 I
- O
mediated O
growth O
inhibition O
in O
EBV O
- O
positive O
B O
cells O
. O

Transfection O
experiments O
with O
c B
- I
myc I
promoter I
constructs I
in O
both O
DHL O
- O
9 O
and O
Raji O
cells O
revealed O
that O
the O
PuF B
site I
functioned O
as O
a O
positive B
regulatory I
element I
in O
B O
cells O
with O
a O
drop O
in O
activity O
with O
mutation O
of O
this O
site O
. O

Alanine O
substitutions O
introduced O
at O
two O
serine O
residues O
positioned O
within O
this O
N B
- I
terminal I
regulatory I
region I
of O
I B
kappa I
B I
alpha I
also O
yielded O
constitutive O
repressors O
that O
escaped O
from O
Tax B
- O
induced O
turnover O
and O
that O
potently O
inhibited O
immune O
activation O
pathways O
for O
NF B
- I
kappa I
B I
induction O
, O
including O
those O
initiated O
from O
antigen B
and I
cytokine I
receptors I
. O

Several O
criteria O
indicated O
that O
the O
defect O
in O
this O
cell O
line O
influences O
the O
activity O
of O
an O
isotype B
- I
specific I
transcription I
factor I
. O

ZEBRA B
is O
a O
bZIP B
transcriptional I
activator I
which O
binds O
as O
a O
dimer O
to O
7 B
- I
bp I
response I
elements I
within O
EBV B
promoters I
and O
is O
directly O
involved O
in O
the O
stimulation O
of O
virus O
replication O
at O
the O
EBV B
lytic I
origin I
. O

Because O
these O
are O
the O
characteristics O
of O
a O
signal B
transducer I
and I
activator I
of I
transcription I
( I
Stat I
) I
protein I
, O
we O
determined O
whether O
antibodies B
to I
Stat I
proteins I
will O
interfere O
with O
gel O
mobility O
shift O
and O
found O
that O
antibodies B
to I
IL I
- I
4 I
Stat I
, O
also O
known O
as O
Stat6 B
, O
but O
not O
antibodies B
to O
other O
Stat B
proteins I
, O
interfere O
with O
the O
formation O
of O
the O
IL B
- I
4 I
NAF I
complex I
. O

Erythroid B
- I
specific I
mRNAs I
encoding O
gamma B
- I
globin I
and O
erythroid B
delta I
- I
aminolevulinate I
synthase I
were O
found O
to O
be O
expressed O
in O
blasts O
from O
most O
of O
these O
cases O
, O
indicating O
that O
majorities O
of O
the O
blasts O
in O
M7 O
and O
TMD O
cases O
have O
erythroid O
and O
megakaryocytic O
phenotypes O
. O

The O
incubation O
with O
transforming B
growth I
factor I
beta I
1 I
and O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
resulted O
in O
a O
5 O
- O
to O
7 O
- O
fold O
increase O
of O
AhR B
mRNA I
. O

In O
vitro O
translated O
Spi B
- I
B I
protein I
can O
bind O
to O
PU B
. I
1 I
binding I
sites I
in O
myeloid B
promoters I
and O
transactivate O
these O
promoters B
in O
nonmyeloid O
cells O
. O

When O
transfected O
into O
K562 O
cells O
, O
which O
express O
zeta B
- I
globin I
, O
comparable O
amounts O
of O
activity O
were O
obtained O
from O
the O
- B
557 I
and I
- I
417 I
zeta I
- I
luciferase I
constructs I
and O
the O
alpha B
- I
luciferase I
constructs I
when O
no O
enhancers B
or O
the O
alpha B
- I
globin I
locus I
enhancers I
were O
used O
. O

The O
ability O
of O
PKC B
- I
epsilon I
to O
induce O
transactivation O
of O
NF B
- I
AT I
- I
1 I
and O
AP B
- I
1 I
was O
similar O
to O
the O
stimulatory O
effect O
of O
a O
constitutively B
activated I
p21ras I
. O

It O
was O
found O
that O
the O
propagation O
of O
the O
Tat B
mutants I
containing O
wild B
- I
type I
LTRs I
was O
less O
efficient O
than O
that O
of O
the O
LTR B
- I
modified I
Tat I
mutants I
. O

Here O
we O
show O
that O
the O
lymphoid B
- I
specific I
transcription I
factor I
Oct I
- I
2A I
plays O
a O
critical O
role O
in O
HLA B
- I
DRA I
gene I
expression O
in O
class O
II O
- O
positive O
B O
cell O
lines O
, O
and O
that O
the O
high B
mobility I
group I
protein I
( O
HMG B
) O
I B
/ I
Y I
binds O
to O
multiple O
sites O
within O
the O
DRA B
promoter I
, O
including O
the O
Oct B
- I
2A I
binding I
site I
. O

In O
lymphoblastoid O
cell O
lines O
, O
six O
EBV B
- I
encoded I
nuclear I
antigens I
( O
EBNA1 B
, I
2 I
, I
3A I
, I
3B I
, I
3C I
, I
- I
LP I
) O
, O
three O
latent B
membrane I
proteins I
( O
LMP1 B
, O
2A B
, O
2B B
) O
, O
and O
two O
nuclear B
RNAs I
( O
EBERs B
) O
are O
expressed O
. O

Also O
, O
the O
BZLF1 B
trans I
- I
activator I
protein I
was O
expressed O
in O
a O
few O
tumor O
cells O
in O
6 O
cases O
, O
indicating O
entry O
into O
the O
lytic O
cycle O
. O

In O
addition O
, O
this O
TR2RE B
- I
SV40 I
can O
function O
as O
a O
repressor O
to O
suppress O
the O
transcriptional O
activities O
of O
both O
SV40 B
early I
and I
late I
promoters I
. O

In O
HeLa O
cells O
stably O
transfected O
with O
the O
HIV B
- I
1 I
tat I
gene I
( O
HeLa O
- O
tat O
cells O
) O
, O
expression O
of O
the O
Tat B
protein I
enhanced O
both O
TNF B
- O
induced O
activation O
of O
NF B
- I
kappa I
B I
and O
TNF B
- O
mediated O
cytotoxicity O
. O

EBNA B
- I
2 I
is O
known O
to O
interact O
with O
the O
cellular B
DNA I
- I
binding I
protein I
J B
kappa I
and O
is O
recruited O
to O
promoters B
containing O
the O
GTGGGAA O
J B
kappa I
recognition I
sequence I
. O

The O
minimal B
EBNA I
- I
2 I
- I
responsive I
LMP I
- I
1 I
promoter I
includes O
one O
J B
kappa I
- I
binding I
site I
, O
and O
we O
now O
show O
that O
mutation O
of O
that O
site O
, O
such O
that O
J B
kappa I
can O
not O
bind O
, O
reduces O
EBNA B
- I
2 I
responsiveness O
by O
60 O
% O
. O

Thus O
, O
although O
the O
kappa B
3 I
element I
has O
little O
sequence O
similarity O
to O
other O
NFATp B
- I
binding I
sites I
, O
it O
appears O
to O
function O
as O
a O
cyclosporin B
- I
sensitive I
promoter I
element I
in O
T O
cells O
by O
virtue O
of O
its O
ability O
to O
bind O
NFATp B
. O

Association O
of O
alterations O
in O
NF B
- I
kappa I
B I
moieties I
with O
HIV O
type O
1 O
proviral O
latency O
in O
certain O
monocytic O
cells O
. O

Human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
replication O
is O
controlled O
by O
a O
complex O
array O
of O
virally B
encoded I
and I
cellular I
proteins I
. O

The O
second O
abnormality O
in O
kappa O
B O
- O
binding O
activity O
in O
T O
cells O
from O
these O
patients O
is O
that O
RelA B
, O
a O
member O
of O
the O
Rel B
homology I
family I
which O
is O
part O
of O
the O
normal O
NF B
- I
kappa I
B I
complex I
, O
was O
not O
induced O
in O
the O
nucleus O
following O
activation O
. O

In O
contrast O
to O
prior O
in O
vitro O
studies O
, O
at O
least O
a O
fraction O
of O
the O
phosphorylated O
form O
of O
I B
kappa I
B I
alpha I
remains O
physically O
associated O
with O
the O
NF B
- I
kappa I
B I
complex I
in O
vivo O
but O
is O
subject O
to O
rapid O
degradation O
, O
thereby O
promoting O
the O
nuclear O
translocation O
of O
the O
active O
NF B
- I
kappa I
B I
complex I
. O

In O
contrast O
to O
prior O
in O
vitro O
studies O
, O
at O
least O
a O
fraction O
of O
the O
phosphorylated O
form O
of O
I B
kappa I
B I
alpha I
remains O
physically O
associated O
with O
the O
NF B
- I
kappa I
B I
complex I
in O
vivo O
but O
is O
subject O
to O
rapid O
degradation O
, O
thereby O
promoting O
the O
nuclear O
translocation O
of O
the O
active O
NF B
- I
kappa I
B I
complex I
. O

We O
report O
here O
that O
three O
copies O
of O
the O
GC B
- I
box I
can O
functionally O
compensate O
for O
the O
GM B
- I
kappa I
B I
/ I
GC I
- I
box I
region I
, O
suggesting O
that O
the O
GC O
- O
motif O
can O
function O
independently O
of O
the O
GM B
- I
kappa I
B I
motif I
. O

It O
encodes O
a O
protein O
predicted O
to O
contain O
688 O
amino O
acid O
residues O
, O
including O
11 O
zinc B
finger I
motifs I
of O
the O
C2H2 B
type I
in O
the O
C B
- I
terminal I
region I
, O
that O
are O
Kruppel O
- O
like O
in O
the O
conservation O
of O
the O
H B
/ I
C I
link I
sequence I
connecting O
them O
. O

Therefore O
, O
we O
propose O
that O
the O
TPA O
/ O
calcium O
- O
activated O
AP B
- I
1 I
/ B
OAP I
element O
is O
the O
main O
target O
of O
positive O
or O
negative O
regulatory O
signals O
influencing O
the O
IL B
- I
2 I
octamer I
motif I
, O
through O
synergism O
with O
Oct B
- I
2 I
and O
antagonism O
by O
RAR B
. O

Furthermore O
, O
multimerized B
region I
II I
sequence I
elements I
enhanced O
the O
activity O
of O
a O
heterologous O
thymidine O
kinase O
promoter O
in O
monocytic O
cells O
but O
not O
other O
cell O
types O
tested O
. O

Mutagenesis O
studies O
, O
and O
the O
use O
of O
a O
reporter O
construct O
containing O
an O
enhancerless O
promoter O
, O
indicate O
that O
these O
transcriptional O
effects O
are O
due O
principally O
to O
the O
22 B
- I
bp I
sequence I
duplication I
and O
the O
NF B
kappa I
B I
site I
contained O
within O
it O
. O

This O
nuclear B
NF I
- I
kappa I
B I
was O
still O
present O
when O
contaminant O
LPS O
was O
removed O
by O
ultrafiltration O
and O
when O
serum O
was O
omitted O
. O

Three O
other O
ATL O
cell O
lines O
( O
TL O
- O
OmI O
, O
H582 O
, O
HuT102 O
) O
were O
found O
to O
have O
little O
mRNA B
for O
the O
LFA B
- I
I I
beta I
chain I
( O
CD18 B
) O
. O

The O
serum B
response I
element I
( O
SRE B
) O
in O
the O
c B
- I
fos I
regulatory I
region I
participates O
in O
induction O
of O
transcription O
by O
various O
growth B
factors I
and O
by O
phorbol O
esters O
and O
subsequent O
squelching O
of O
transcription O
. O

Thus O
, O
the O
use O
of O
DNase B
I I
allowed O
us O
, O
for O
the O
first O
time O
, O
to O
correlate O
the O
AIR B
- I
1 I
locus I
defect I
with O
class B
II I
promoter I
occupancy O
alterations O
and O
distinguish O
these O
alterations O
from O
the O
ones O
observed O
in O
phenotypically O
similar O
but O
genetically O
distinct O
MHC O
class O
II O
- O
negative O
cells O
. O

Among O
258 O
X O
chromosome O
- O
containing O
sperm O
, O
19 O
% O
had O
a O
repeat O
number O
equal O
to O
the O
donor B
' I
s I
somatic I
DNA I
( O
47 O
repeats O
) O
, O
66 O
% O
were O
expansions O
and O
15 O
% O
were O
contractions O
. O

The O
increase O
in O
IL B
- I
2 I
gene O
expression O
triggered O
by O
CD28 B
involves O
a O
kappa B
B I
- I
like I
sequence I
in O
the O
5 B
' I
- I
regulatory I
region I
of O
the O
IL B
- I
2 I
promoter I
, O
called O
CD28 B
- I
responsive I
element I
. O

The O
increase O
in O
IL B
- I
2 I
gene O
expression O
triggered O
by O
CD28 B
involves O
a O
kappa B
B I
- I
like I
sequence I
in O
the O
5 B
' I
- I
regulatory I
region I
of O
the O
IL B
- I
2 I
promoter I
, O
called O
CD28 B
- I
responsive I
element I
. O

Here O
we O
report O
that O
CD28 B
engagement O
, O
however O
, O
exerts O
opposite O
effects O
on O
the O
transcription B
factor I
AP I
- I
1 I
. O

To O
identify O
ets B
- I
related I
transcriptional I
regulators I
expressed O
in O
pre O
- O
B O
lymphocytes O
that O
may O
interact O
with O
either O
the O
pi B
or O
the O
microB B
site I
, O
we O
have O
used O
a O
PCR O
approach O
with O
degenerate O
oligonucleotides O
encoding O
conserved O
sequences O
in O
all O
members O
of O
the O
ets B
family I
. O

We O
have O
cloned O
the O
gene O
for O
a O
new O
ets B
- I
related I
transcription I
factor I
, O
ERP B
( O
ets B
- I
related I
protein I
) O
, O
from O
the O
murine O
pre O
- O
B O
cell O
line O
BASC O
6C2 O
and O
from O
mouse O
lung O
tissue O
. O

In O
vivo O
protein O
- O
DNA O
contacts O
are O
detectable O
at O
Ii B
kappa I
B I
- I
1 I
in O
cell O
lines O
in O
which O
this O
site O
is O
functional O
as O
either O
a O
positive B
or I
negative I
regulator I
. O

Ii B
kappa I
B I
- I
2 I
is O
a O
site O
of O
positive O
regulation O
in O
B O
- O
cell O
lines O
and O
a O
site O
of O
negative O
regulation O
in O
H9 O
T O
cells O
, O
myelomonocytic O
, O
and O
glial O
cell O
lines O
. O

OBJECTIVE O
: O
To O
determine O
whether O
activation O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
replication O
in O
tumour O
cells O
of O
AIDS O
- O
related O
non O
- O
Hodgkin O
' O
s O
lymphoma O
( O
ARNHL O
) O
is O
correlated O
with O
CD4 B
+ I
cell O
counts O
and O
influences O
antibody O
response O
to O
EBV O
[ O
anti B
- I
Z I
Epstein I
- I
Barr I
replicative I
activator I
( O
ZEBRA B
) O
, O
anti B
- I
early I
antigen I
( O
EA B
) O
, O
anti B
- I
viral I
capsid I
antigen I
( O
VCA B
) O
] O
. O

PDTC O
or O
N O
- O
acetylcysteine O
dose O
dependently O
reduced O
TNF B
- I
induced I
VCAM I
- I
1 I
but O
not O
ICAM B
- I
1 I
surface I
protein I
( O
also O
in O
human O
umbilical O
arterial O
endothelial O
cells O
) O
and O
mRNA O
expression O
( O
by O
70 O
% O
at O
100 O
mumol O
/ O
L O
PDTC O
) O
in O
HUVECs O
as O
assessed O
by O
flow O
cytometry O
and O
polymerase O
chain O
reaction O
. O

Activation O
of O
the O
interleukin B
6 I
gene I
by O
Mycobacterium O
tuberculosis O
or O
lipopolysaccharide O
is O
mediated O
by O
nuclear B
factors I
NF I
- I
IL6 I
and O
NF B
- I
kappa I
B I
[ O
published O
erratum O
appears O
in O
Proc O
Natl O
Acad O
Sci O
U O
S O
A O
1995 O
Apr O
11 O
; O
92 O
( O
8 O
) O
: O
3632 O
] O

Two O
nuclear B
factor I
NF I
- I
IL6 I
( O
positions O
- B
153 I
to I
- I
145 I
and O
- O
83 O
to O
- O
75 O
) O
and O
one O
nuclear B
factor I
NF I
- I
kappa I
B I
( I
positions I
- I
72 I
to I
- I
63 I
) I
motifs I
are O
present O
within O
this O
fragment O
. O

Two O
nuclear B
factor I
NF I
- I
IL6 I
( O
positions O
- B
153 I
to I
- I
145 I
and O
- O
83 O
to O
- O
75 O
) O
and O
one O
nuclear B
factor I
NF I
- I
kappa I
B I
( I
positions I
- I
72 I
to I
- I
63 I
) I
motifs I
are O
present O
within O
this O
fragment O
. O

We O
conclude O
that O
the O
NF B
- I
IL6 I
and I
NF I
- I
kappa I
B I
sites I
mediate O
IL B
- I
6 I
induction O
in O
response O
to O
both O
LPS O
and O
LAM B
, O
acting O
as O
bacterial B
or I
mycobacterial I
response I
elements I
. O

Furthermore O
, O
we O
found O
that O
20 O
% O
to O
25 O
% O
of O
both O
the O
adhesion B
protein I
Mac I
- I
1 I
and O
the O
NADPH B
- I
oxidase I
component I
cytochrome I
b558 B
is O
localized O
in O
gelatinase B
granules O
. O

Furthermore O
, O
we O
found O
that O
20 O
% O
to O
25 O
% O
of O
both O
the O
adhesion B
protein I
Mac I
- I
1 I
and O
the O
NADPH B
- I
oxidase I
component I
cytochrome I
b558 B
is O
localized O
in O
gelatinase B
granules O
. O

To O
test O
this O
hypothesis O
, O
light B
- I
chain I
gene I
structure I
was O
examined O
in O
pre O
- O
B O
cells O
transformed O
by O
temperature O
- O
sensitive O
mutants O
of O
the O
Abelson O
virus O
and O
in O
derivatives O
that O
survive O
at O
the O
nonpermissive O
temperature O
because O
they O
express O
a O
human B
BCL I
- I
2 I
gene I
. O

To O
test O
this O
hypothesis O
, O
light B
- I
chain I
gene I
structure I
was O
examined O
in O
pre O
- O
B O
cells O
transformed O
by O
temperature O
- O
sensitive O
mutants O
of O
the O
Abelson O
virus O
and O
in O
derivatives O
that O
survive O
at O
the O
nonpermissive O
temperature O
because O
they O
express O
a O
human B
BCL I
- I
2 I
gene I
. O

The O
expression O
of O
the O
M B
- I
CSF I
gene I
, O
that O
has O
been O
recently O
reassigned O
to O
the O
short B
arm I
of I
chromosome I
1 I
( O
lp B
) O
, O
was O
also O
investigated O
. O

Similar O
analysis O
of O
poly B
( I
A I
) I
RNA I
from O
a O
variety O
of O
adult O
tissues O
demonstrated O
HB9 B
transcripts O
in O
pancreas O
, O
small O
intestine O
, O
and O
colon O
. O

Retinoic O
acid O
- O
induced O
expression O
of O
CD38 B
antigen I
in O
myeloid O
cells O
is O
mediated O
through O
retinoic B
acid I
receptor I
- I
alpha I
. O

Some O
antioxidants O
inhibit O
, O
in O
a O
co O
- O
ordinate O
fashion O
, O
the O
production O
of O
tumor B
necrosis I
factor I
- I
alpha I
, O
IL B
- I
beta I
, O
and O
IL B
- I
6 I
by O
human O
peripheral O
blood O
mononuclear O
cells O
. O

To O
characterize O
mechanisms O
responsible O
for O
these O
LIF B
effects O
, O
levels O
of O
HIV B
mRNA I
, O
activation O
of O
the O
DNA B
binding I
protein I
nuclear I
factor I
( B
NF I
) I
- I
kB I
, O
signal O
transduction O
pathways O
, O
and O
potential O
interactions O
with O
other O
cytokines B
were O
analyzed O
. O

To O
characterize O
mechanisms O
responsible O
for O
these O
LIF B
effects O
, O
levels O
of O
HIV B
mRNA I
, O
activation O
of O
the O
DNA B
binding I
protein I
nuclear I
factor I
( B
NF I
) I
- I
kB I
, O
signal O
transduction O
pathways O
, O
and O
potential O
interactions O
with O
other O
cytokines B
were O
analyzed O
. O

In O
order O
to O
study O
CD14 B
gene I
regulation O
, O
the O
human B
CD14 I
gene I
was O
cloned O
from O
a O
partial O
EcoRI B
digested I
chromosome I
5 I
library I
. O

Both O
stimuli O
induced O
the O
appearance O
of O
the O
NF B
- I
kappa I
B I
components I
( O
c B
- I
Rel I
, O
p65 B
( O
RelA B
) O
, O
and O
p50 B
( O
NF B
- I
kappa I
B1 I
) O
) O
and O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
in O
the O
nucleus O
. O

CD14 B
- O
mediated O
translocation O
of O
nuclear B
factor I
- I
kappa I
B I
induced O
by O
lipopolysaccharide O
does O
not O
require O
tyrosine B
kinase I
activity O
. O

Resolution O
of O
the O
NF B
- I
kappa I
B I
complex I
in O
gel O
shift O
analysis O
shows O
that O
the O
binding B
protein I
, O
mobilized O
in O
naive O
Mono O
Mac O
6 O
cells O
, O
consists O
mainly O
of O
p50 B
- I
p65 I
heterodimers I
, O
while O
in O
tolerant O
cells O
, O
the O
p50 B
homodimer I
is O
predominant O
. O

A O
new O
exon B
containing O
a O
highly O
basic O
region O
( O
4c O
) O
was O
characterized O
, O
between B
exons I
4 I
and I
5 I
. O

Treatment O
of O
human O
erythrocytes O
with O
10 O
microM O
sodium O
orthovanadate O
( O
NaOV O
) O
, O
an O
inhibitor O
of O
plasma B
membrane I
Ca I
- I
ATPase I
and O
phosphotyrosine B
phosphatase I
, O
decreased O
parasitemia O
by O
30 O
% O
. O

Neutral B
sphingomyelinase I
( O
SMase B
) O
can O
be O
activated O
by O
extracellular O
signals O
to O
produce O
ceramide O
, O
which O
may O
affect O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
activities O
. O

The O
transmembrane O
domains O
are O
well O
conserved O
, O
but O
there O
is O
striking O
sequence O
divergence O
of O
the O
carboxy B
- I
terminal I
cytoplasmic I
domain I
essential O
for O
B O
- O
cell O
immortalization O
and O
interaction O
with O
the O
tumor B
necrosis I
factor I
receptor I
signaling O
pathway O
. O

Using O
fluorescence O
in O
situ O
hybridization O
( O
FISH O
) O
, O
we O
show O
here O
that O
the O
genes B
encoding O
the O
TATA B
- I
box I
binding I
protein I
( O
TBP B
) O
, O
TFIIB B
, O
TFIIE B
alpha I
, O
TFIIE B
beta I
, O
RAP30 B
, O
RAP74 B
and O
the O
62 B
kDa I
subunit I
, O
of O
TFIIH B
are O
located O
at O
the O
human B
chromosomal I
bands I
6q26 I
- I
27 I
, I
1p21 I
- I
22 I
, I
3q21 I
- I
24 I
, I
8p12 I
, I
13q14 I
, I
19p13 I
. I
3 I
and I
11p14 I
- I
15 I
. I
1 I
, O
respectively O
. O

Although O
no O
proof O
yet O
exists O
of O
a O
role O
for O
these O
lesions O
in O
DLCL O
pathogenesis O
, O
the O
feature O
of O
the O
BCL B
- I
6 I
gene I
product I
, O
its O
specific O
pattern O
of O
expression O
in O
B O
cells O
, O
and O
the O
clustering O
of O
lesions O
disrupting O
its O
regulatory O
domain O
strongly O
suggest O
that O
deregulation O
of O
BCL B
- I
6 I
expression O
may O
contribute O
to O
DLCL O
development O
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 B
/ I
p50 I
subunit I
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial B
adhesion I
molecule I
- I
1 I
( O
CD62E B
) O
and O
vascular B
adhesion I
molecule I
- I
1 I
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

Flow O
cytometry O
analyses O
on O
cultured O
cells O
that O
were O
treated O
with O
tepoxalin O
or O
antisense O
oligonucleotides O
to O
the O
P65 B
/ I
p50 I
subunit I
of O
NF B
- I
kappa I
B I
, O
and O
then O
stimulated O
with O
PMA O
, O
revealed O
a O
reduced O
expression O
of O
CD11b B
/ I
CD18 I
on O
monocytic O
HL60 O
cells O
, O
and O
endothelial B
adhesion I
molecule I
- I
1 I
( O
CD62E B
) O
and O
vascular B
adhesion I
molecule I
- I
1 I
( O
CD106 B
) O
on O
human O
umbilical O
vein O
endothelial O
cells O
. O

NH2 B
- O
terminal O
amino O
acid O
sequence O
analysis O
identified O
the O
140 B
- I
kDa I
surface I
antigen I
for O
mAb B
J393 I
as O
CD43 B
/ I
leukosialin I
, O
the O
major O
sialoglycoprotein B
of O
leukocytes O
. O

Consequently O
, O
the O
present O
study O
was O
addressed O
to O
understand O
this O
phenomenon O
and O
revealed O
the O
existence O
of O
a O
unique B
47 I
kDa I
protein I
factor I
having O
affinity O
for O
this O
SRE B
sequence I
in O
lymphocytes O
from O
normal O
subjects O
as O
well O
as O
its O
absence O
in O
lymphocytes O
from O
untreated O
CML O
patients O
. O

To O
understand O
the O
mechanism O
by O
which O
PRL B
regulates O
the O
biphasic O
expression O
of O
IRF B
- I
1 I
, O
we O
cloned O
the O
rat B
IRF I
- I
1 I
gene I
and O
functionally O
characterized O
the O
IRF B
- I
1 I
promoter I
. O

Hence O
, O
the O
PRL B
- O
induced O
biphasic O
expression O
of O
the O
IRF B
- I
1 I
gene I
appears O
to O
be O
controlled O
by O
separate O
PRL B
- I
responsive I
elements I
: O
elements O
in O
the O
first O
0 O
. O
2 O
kb O
of O
the O
IRF B
- I
1 I
promoter I
region I
act O
during O
early O
activation O
, O
and O
elements O
between O
0 O
. O
2 O
and O
1 O
. O
7 O
kb O
act O
in O
concert O
with O
the O
proximal O
0 O
. O
2 O
- O
kb O
region O
during O
S O
phase O
progression O
. O

We O
have O
shown O
elsewhere O
that O
both O
the O
major B
immediate I
- I
early I
gene I
( O
MIE B
) O
and O
lytic O
cycle O
infectious O
progeny O
virus O
expression O
can O
be O
induced O
in O
otherwise O
nonpermissive O
monocyte O
- O
like O
U O
- O
937 O
cell O
cultures O
infected O
with O
either O
human O
CMV O
( O
HCMV O
) O
or O
simian O
CMV O
( O
SCMV O
) O
by O
treatment O
with O
the O
phorbol O
ester O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
. O

Two O
pp56 B
( I
lck I
) I
mutants I
lacking O
either O
the O
entire O
catalytic B
domain I
or O
the O
entire O
NH2 B
regulatory B
domain I
were O
generated O
, O
and O
their O
abilities O
to O
trigger O
transactivation O
of O
the O
TCR B
- I
regulated I
nuclear I
factor I
of I
activated I
T I
cells I
( I
NF I
- I
AT I
) I
region I
of O
the O
IL B
- I
2 I
promoter I
were O
compared O
. O

Tumor B
necrosis I
factor I
receptor I
- I
1 I
( O
TNFR B
- I
1 I
) O
and O
CD95 B
( O
also O
called O
Fas B
or O
APO B
- I
1 I
) O
are O
cytokine B
receptors I
that O
engage O
the O
apoptosis O
pathway O
through O
a O
region O
of O
intracellular O
homology O
, O
designated O
the O
` O
` O
death B
domain I
. O
' O
' O
Another O
death B
domain I
- I
containing I
member I
of O
the O
TNFR B
family I
, O
death B
receptor I
3 I
( O
DR3 B
) O
, O
was O
identified O
and O
was O
shown O
to O
induce O
both O
apoptosis O
and O
activation O
of O
nuclear B
factor I
kappaB I
. O

Cotransfection O
of O
a O
YB B
- I
1 I
expression I
plasmid I
increases O
HTLV O
- O
I O
basal O
transcription O
approximately O
14 O
- O
fold O
in O
Jurkat O
T O
lymphocytes O
. O

Calcineurin B
acts O
in O
synergy O
with O
PMA O
to O
inactivate O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

Calcineurin B
stimulates O
the O
NF B
- I
kappa I
B I
element I
by O
enhancing O
inactivation O
of O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
, O
thereby O
increasing O
the O
amount O
of O
nuclear O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
. O

Calcineurin B
stimulates O
the O
NF B
- I
kappa I
B I
element I
by O
enhancing O
inactivation O
of O
I B
kappa I
B I
/ I
MAD3 I
, O
an O
inhibitor O
of O
NF B
- I
kappa I
B I
, O
thereby O
increasing O
the O
amount O
of O
nuclear O
NF B
- I
kappa I
B I
DNA O
binding O
activity O
. O

Inhibition O
of O
membrane O
IL B
- I
2R I
alpha I
and O
IL B
- I
2R I
beta I
expression O
by O
10 O
( O
- O
6 O
) O
M O
DM O
was O
partially O
reversible O
by O
recombinant B
human I
IL I
- I
2 I
( O
rhIL B
- I
2 I
) O
. O

These O
findings O
thus O
reveal O
the O
presence O
of O
a O
second O
inducible O
autoregulated O
inhibitory O
pathway O
that O
helps O
ensure O
the O
rapid O
but O
transient O
action O
of O
nuclear B
NF I
- I
kappa I
B I
. O

To O
investigate O
the O
mechanisms O
of O
transcriptional O
activation O
of O
interleukin B
- I
1beta I
( O
IL B
- I
1beta I
) O
in O
non O
- O
monocytic O
cells O
, O
we O
constructed O
a O
series O
of O
reporter O
plasmids O
with O
the O
bacterial O
chloramphenicol O
acetyltransferase O
gene O
linked O
to O
various O
parts O
of O
the O
human B
IL I
- I
1beta I
promoter I
and O
performed O
transient O
transfection O
experiments O
. O

Deletion O
of O
the O
glucocorticoid O
response O
elements O
located O
at O
ca B
. I
bp I
- I
850 I
upstream O
of O
Cp B
did O
not O
result O
in O
a O
significant O
loss O
in O
activity O
. O

Nuclear O
translocation O
of O
NF B
- I
kappaB I
subunits I
may O
ultimately O
increase O
the O
intracellular O
pool O
of O
NF B
- I
kappaB I
/ I
IkappaBalpha I
by O
an O
autoregulatory O
mechanism O
. O

The O
transcriptionally B
regulatory I
regions I
of O
the O
lymphomagenic O
Akv O
and O
SL3 O
- O
3 O
murine O
leukemia O
retroviruses O
( O
MLVs O
) O
contain O
two O
types O
of O
E B
- I
box I
consensus I
motifs I
, O
CAGATG O
. O

ALF1 B
transactivated O
transcription O
of O
Akv O
MLV O
through O
the O
two O
E B
( I
gre I
) I
motifs I
equally O
, O
whereas O
E2A B
protein I
required O
the O
promoter O
- O
proximal O
E B
( I
gre I
) I
motif O
. O

Although O
NGFI B
- I
B I
/ I
nur77 I
is O
essential O
for O
TCR O
- O
mediated O
apoptosis O
in O
T B
- I
cell I
hybridomas I
, O
the O
reports O
on O
nur77 O
knock O
- O
out O
mice O
and O
nur77 O
dominant O
negative O
transgenic O
mice O
suggest O
that O
there O
is O
a O
functional O
redundancy O
among O
NGFI B
- I
B I
/ I
nur77 I
family I
. O

MNDA B
( O
myeloid B
cell I
nuclear I
differentiation I
antigen I
) O
is O
an O
interferon B
alpha I
regulated I
nuclear I
protein I
expressed O
only O
in O
cells O
of O
the O
human O
myelomonocytic O
lineage O
. O

MNDA B
( O
myeloid B
cell I
nuclear I
differentiation I
antigen I
) O
is O
an O
interferon B
alpha I
regulated I
nuclear I
protein I
expressed O
only O
in O
cells O
of O
the O
human O
myelomonocytic O
lineage O
. O

Thus O
, O
IL B
- I
2 I
- O
induced O
IL B
- I
2R I
alpha I
promoter I
activity O
requires O
a O
complex B
upstream I
element I
, O
which O
appears O
to O
contain O
binding B
sites I
for O
both O
positive B
and I
negative I
regulatory I
factors I
. O

Thus O
, O
IL B
- I
2 I
- O
induced O
IL B
- I
2R I
alpha I
promoter I
activity O
requires O
a O
complex B
upstream I
element I
, O
which O
appears O
to O
contain O
binding B
sites I
for O
both O
positive B
and I
negative I
regulatory I
factors I
. O

Here O
we O
describe O
the O
isolation O
and O
expression O
of O
a O
cDNA B
encoding O
PTF B
beta I
, O
as O
well O
as O
functional O
studies O
using O
anti B
- I
PTF I
beta I
antibodies I
. O

We O
report O
here O
on O
the O
identification O
of O
a O
17 B
kDa I
variant I
of O
the O
14 B
kDa I
Id I
- I
3 I
protein O
termed O
Id B
- I
3L I
( O
long O
version O
) O
which O
possesses O
a O
unique O
60 B
amino I
acid I
carboxy I
- I
terminus I
generated O
by O
read O
through O
of O
a O
' O
coding B
intron I
' O
and O
alternative O
splicing O
. O

Tyloxapol O
inhibits O
activation O
of O
the O
transcription B
factor I
nuclear I
factor I
- I
kappa I
B I
( O
NK B
- I
kappa I
B I
) O
, O
reduces O
resting O
secretion O
of O
the O
cytokine B
interleukin B
- I
8 I
( O
IL B
- I
8 I
) O
in O
cultured O
human O
monocytes O
, O
and O
inhibits O
lipopolysaccharide O
( O
LPS O
) O
- O
stimulated O
release O
of O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
IL B
- I
1 I
beta I
, O
IL B
- I
6 I
, O
IL B
- I
8 I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
( O
GM B
- I
CSF I
) O
, O
and O
the O

Approximately O
40 O
% O
of O
diffuse O
large O
cell O
lymphoma O
are O
associated O
with O
chromosomal O
translocations O
that O
deregulate O
the O
expression O
of O
the O
BCL6 B
gene I
by O
juxtaposing O
heterologous B
promoters I
to O
the O
BCL B
- I
6 I
coding I
domain I
. O

Analysis O
of O
the O
ligand B
- I
binding I
domain I
of O
human B
retinoic I
acid I
receptor I
alpha I
by O
site O
- O
directed O
mutagenesis O
. O

Epstein O
- O
Barr O
viral O
latency O
is O
disrupted O
by O
the O
immediate B
- I
early I
BRLF1 I
protein I
through O
a O
cell O
- O
specific O
mechanism O
. O

Nuclear B
factor I
of I
activated I
T I
cells I
- I
family I
proteins I
( O
NFAT1 B
/ I
NFATp I
, O
NFATc B
, O
NFAT3 B
, O
and O
NFAT4 B
/ I
NFATx I
/ I
NFATc3 I
) O
play O
a O
key O
role O
in O
the O
transcription O
of O
cytokine B
genes I
and O
other O
genes O
during O
the O
immune O
response O
. O

Our O
results O
suggest O
that O
PKA B
inhibits O
T O
cell O
activation O
by O
interfering O
with O
multiple O
events O
along O
the O
two O
signaling O
pathways O
operating O
downstream O
of O
the O
TCR B
and O
the O
CD28 B
co I
- I
receptor I
molecules I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

To O
determine O
the O
contribution O
of O
the O
cytoplasmic B
domain I
of O
the O
IL B
- I
7 I
receptor I
alpha I
chain I
( O
IL B
- I
7R I
alpha I
) O
to O
activation O
of O
STAT B
proteins I
, O
transfectants O
of O
the O
murine O
pro O
- O
B O
cell O
line O
BAF3 O
were O
made O
that O
express O
chimeric B
receptors I
consisting O
of O
the O
extracellular B
domain I
of O
human B
granulocyte I
colony I
- I
stimulating I
factor I
receptor I
( O
G B
- I
CSF I
- I
R I
) O
and O
the O
transmembrane B
and I
intracellular I
domains I
of O
human B
IL I
- I
7R I
alpha I
. O

GM B
- I
CSF I
gene I
activation O
in O
T O
cells O
is O
known O
to O
involve O
the O
transcription B
factors I
nuclear B
factor I
- I
kappa I
B I
, O
AP B
- I
1 I
, O
NFAT B
, O
and O
Sp1 O
. O

The O
AML1 B
and I
CBF I
beta I
genes I
that O
encode O
CBF B
each O
have O
the O
ability O
to O
influence O
cell O
growth O
and O
differentiation O
and O
have O
been O
implicated O
as O
proto B
- I
oncogenes I
in O
acute O
myeloid O
leukemia O
. O

Tyrosine B
kinase I
and O
cAMP B
- I
dependent I
protein I
kinase I
activities O
in O
CD40 O
- O
activated O
human O
B O
lymphocytes O
. O

Direct O
evidence O
that O
N O
- O
acetylcysteine O
( O
NAC O
) O
enhances O
the O
immune O
response O
of O
peripheral O
blood O
T O
cells O
at O
the O
level O
of O
NF B
( I
kappa I
) I
B I
is O
presented O
. O

Our O
data O
support O
the O
notion O
that O
NF B
( I
kappa I
) I
B I
and O
I B
( I
kappa I
) I
B I
proteases I
play O
obligate O
roles O
in O
T O
cell O
activation O
and O
mitogenesis O
, O
roles O
that O
are O
enhanced O
significantly O
by O
NAC O
. O

Yet O
, O
little O
is O
known O
as O
to O
how O
the O
RA B
and I
VitD3 I
receptor I
network I
operates O
in O
hematopoietic O
cells O
, O
and O
whether O
receptor O
interactions O
can O
explain O
the O
interplay O
between O
the O
RA O
- O
and O
VitD3 O
- O
signaling O
pathways O
during O
differentiation O
. O

Therefore O
, O
we O
analyzed O
the O
expression O
, O
DNA O
binding O
, O
and O
transcriptional O
activity O
of O
the O
endogenous B
RA I
and I
VitD3 I
receptors I
[ O
retinoic B
acid I
receptors I
( O
RARs B
) O
, O
retinoid B
X I
receptors I
( O
RXRs B
) O
, O
and O
VitD3 B
receptor I
( O
VDR B
) O
] O
in O
the O
U O
- O
937 O
cell O
line O
, O
in O
which O
RA O
and O
VitD3 O
induce O
distinct O
monocytic O
differentiation O
pathways O
. O

Freshly O
isolated O
monocytes O
expressed O
94 B
- I
kD I
STAT5A I
, O
92 O
- O
kD O
STAT5B B
, O
and O
an O
80 B
- I
kD I
STAT5A I
molecule I
. O

To O
investigate O
the O
molecular O
mechanism O
of O
the O
inhibitory O
effect O
on O
transcriptional O
or O
post O
- O
transcriptional O
regulation O
of O
IL B
- I
6 I
gene I
expression O
by O
IL B
- I
4 I
and O
IL B
- I
10 I
, O
we O
studied O
IL B
- I
6 I
production O
, O
expression O
level O
of O
IL B
- I
6 I
mRNA I
, O
IL B
- I
6 I
promoter O
activity O
, O
transcriptional O
activity O
of O
NF B
- I
kappaB I
and O
NF B
- I
IL I
- I
6 I
, O
and O
IL B
- I
6 I
mRNA I
stability O
in O
human O
monocytic O
cell O
lines O
, O
THP O
- O
1 O
and O
U937 O
, O
stimulated O
by O
PMA O
and O
LPS O
in O
the O
absence O
or O
the O
presence O
of O
IL B
- I
4 I
or O
IL B
- I
10 I
. O

In O
chloramphenicol B
acetyltransferase I
assays O
, O
utilizing O
the O
transient O
transfection O
of O
a O
chloramphenicol B
acetyltransferase I
reporter I
plasmid I
containing O
the O
IL B
- I
6 I
gene I
promoter I
, O
IL B
- I
4 I
, O
but O
not O
IL B
- I
10 I
, O
suppressed O
the O
transcriptional O
activity O
of O
the O
IL O
- O
6 O
gene O
promoter O
stimulated O
by O
PMA O
and O
LPS O
. O

Electrophoretic O
mobility O
shift O
assay O
showed O
the O
induction O
of O
a O
CsA B
- I
resistant I
NFAT I
complex I
in O
the O
nuclear O
extracts O
of O
peripheral O
blood O
T O
cells O
stimulated O
with O
PMA O
plus O
alphaCD28 B
. O

There O
are O
four O
putative O
NF B
- I
kappa I
B I
binding I
sites I
( O
kappa B
B I
- I
1 I
, O
kappa B
B I
- I
2 I
, O
kappa B
B I
- I
3 I
, O
kappa B
B I
- I
4 I
) O
in O
human B
TNF I
- I
alpha I
promoter I
. O

Biochemical O
analysis O
of O
the O
region O
- B
158 I
/ I
- I
90 I
revealed O
a O
binding O
site O
for O
transcription B
factors I
of O
the O
polyomavirus B
enhancer I
- I
binding I
protein I
2 I
/ I
core I
- I
binding I
factor I
( I
PEBP2 I
/ I
CBF I
) I
family I
at O
position B
- I
103 I
. O

Expression O
of O
the O
MAP B
kinase I
- I
specific I
phosphatase I
, O
MKP B
- I
1 I
, O
which O
blocks O
ERK B
activation O
, O
inhibited O
IL B
- I
2 I
promoter I
and O
NF B
- I
AT I
- O
driven O
transcription O
stimulated O
by O
a O
calcium O
ionophore O
and O
PMA O
, O
and O
in O
addition O
, O
MKP B
- I
1 I
neutralized O
the O
transcriptional O
enhancement O
caused O
by O
active O
Raf O
- O
1 O
and O
MEK1 O
expression O
. O

Costimulation O
of O
U1 O
cells O
with O
LPS O
plus O
GM B
- I
CSF I
resulted O
in O
the O
accumulation O
of O
steady O
- O
state O
levels O
of O
HIV B
RNA I
; O
however O
, O
only O
a O
weak O
induction O
of O
HIV B
long I
terminal I
repeat I
- O
driven O
transcription O
, O
which O
was O
not O
associated O
with O
the O
activation O
of O
the O
cellular B
transcription I
factor I
nuclear B
factor I
- I
kappa I
B I
, O
was O
noted O
. O

However O
, O
synthesis O
of O
the O
26 B
- I
kDa I
membrane I
form I
of O
TNF B
was O
effectively O
blocked O
by O
CNI O
- O
1493 O
. O

r B
- I
hTBP I
- I
1 I
and O
rhu B
TNFR I
: I
Fc I
also O
decreased O
p24 B
antigen I
synthesized O
by O
U1 O
cells O
in O
response O
to O
other O
stimuli O
, O
including O
phytohemagglutinin B
( I
PHA I
) I
- I
induced I
supernatant I
, O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
, O
interleukin B
- I
6 I
, O
and O
TNF B
. O

Addition O
of O
r B
- I
hTBP I
- I
1 I
to O
U1 O
cells O
during O
the O
last O
4 O
h O
of O
a O
24 O
h O
incubation O
with O
PMA O
still O
inhibited O
p24 B
antigen I
production O
by O
15 O
% O
. O

r B
- I
hTBP I
- I
1 I
also O
partially O
reversed O
inhibition O
of O
U1 O
cellular O
proliferation O
caused O
by O
PMA O
. O

The O
effects O
of O
IFN B
- I
gamma I
on O
the O
transcription B
factors I
were O
specific O
, O
since O
no O
change O
was O
observed O
in O
the O
expression O
of O
NF B
- I
IL I
- I
6 I
or O
I B
kappa I
B I
alpha I
, O
the O
inhibitor O
of O
NF B
- I
kappa I
B I
. O

Here O
we O
identify O
the O
gene O
encoding O
the O
lymphocyte B
homing I
and I
migration I
protein I
CD44 B
as O
a O
target O
of O
EGR1 B
regulation O
in O
B O
cells O
. O

Although O
a O
13 B
- I
kilobase I
- I
pair I
( I
kb I
) I
human I
c I
- I
fes I
transgene I
exhibits O
high O
levels O
of O
expression O
in O
mice O
, O
the O
sequences O
that O
confer O
myeloid O
- O
cell O
- O
specific O
expression O
of O
the O
human B
c I
- I
fes I
gene I
have O
not O
been O
defined O
. O

Previous O
studies O
have O
shown O
that O
retinoic O
acid O
( O
RA O
) O
, O
similar O
to O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
, O
can O
act O
as O
a O
bifunctional O
regulator O
of O
the O
growth O
of O
bone O
marrow O
progenitors O
, O
in O
that O
it O
can O
stimulate O
granulocyte O
- O
macrophage O
colony O
- O
stimulating O
factor O
( O
GM O
- O
CSF O
) O
- O
or O
interleukin O
- O
3 O
( O
IL O
- O
3 O
) O
- O
induced O
GM O
colony O
formation O
, O
but O
potently O
inhibit O
G B
- I
CSF I
- O
induced O
growth O
. O

After O
treatment O
of O
APL O
cells O
with O
AM580 O
either O
alone O
or O
in O
combination O
with O
granulocyte B
colony I
- I
stimulating I
factor I
( O
G B
- I
CSF I
) O
, O
the O
compound O
induces O
granulocytic O
maturation O
, O
as O
assessed O
by O
determination O
of O
the O
levels O
of O
leukocyte B
alkaline I
phosphatase I
, I
CD11b I
, I
CD33 I
, I
and I
G I
- I
CSF I
receptor I
mRNA I
, O
at O
concentrations O
that O
are O
10 O
- O
to O
100 O
- O
fold O
lower O
than O
those O
of O
ATRA O
necessary O
to O
produce O
similar O
effects O
. O

Nuclear B
factors I
from O
unstimulated O
, O
but O
not O
from O
activated O
cells O
, O
bound O
a O
site O
, O
META B
( I
D I
- I
) I
, O
adjacent O
to O
META B
( I
D I
+ I
) I
. O

Nuclear B
factors I
from O
unstimulated O
, O
but O
not O
from O
activated O
cells O
, O
bound O
a O
site O
, O
META B
( I
D I
- I
) I
, O
adjacent O
to O
META B
( I
D I
+ I
) I
. O

Ca2 B
+ I
- I
modulating I
cyclophilin I
ligand I
( O
CAML B
) O
was O
originally O
described O
as O
a O
cyclophilin B
B I
- I
binding I
protein I
whose O
overexpression O
in O
T O
cells O
causes O
a O
rise O
in O
intracellular O
calcium O
, O
thus O
activating O
transcription B
factors I
responsible O
for O
the O
early O
immune O
response O
. O

Mutation O
of O
the O
consensus B
AP I
- I
1 I
/ I
CRE I
site I
within O
ZII B
abolished O
the O
inducibility O
of O
Zp B
by O
HHV O
- O
6 O
, O
whereas O
positioning O
of O
the O
ZII B
domain I
upstream O
of O
the O
beta B
- I
globin I
minimal I
promoter I
conferred O
responsiveness O
following O
HHV O
- O
6 O
infection O
. O

The O
lymphoid B
- I
specific I
transcription I
factor I
Oct B
- I
2a I
is O
implicated O
in O
B O
cell O
- O
specific O
transcriptional O
activity O
via O
the O
octamer O
motif O
. O

Structure O
/ O
function O
analysis O
of O
various O
Oct B
- I
2a I
effector I
regions I
in O
the O
context O
of O
the O
GAL4 B
DNA I
- I
binding I
domain I
revealed O
that O
Oct B
- I
2a I
contains O
two O
functionally O
different O
activation B
domains I
at O
the O
N B
and I
the I
C I
termini I
. O

Structure O
/ O
function O
analysis O
of O
various O
Oct B
- I
2a I
effector I
regions I
in O
the O
context O
of O
the O
GAL4 B
DNA I
- I
binding I
domain I
revealed O
that O
Oct B
- I
2a I
contains O
two O
functionally O
different O
activation B
domains I
at O
the O
N B
and I
the I
C I
termini I
. O

Structure O
/ O
function O
analysis O
of O
various O
Oct B
- I
2a I
effector I
regions I
in O
the O
context O
of O
the O
GAL4 B
DNA I
- I
binding I
domain I
revealed O
that O
Oct B
- I
2a I
contains O
two O
functionally O
different O
activation B
domains I
at O
the O
N B
and I
the I
C I
termini I
. O

More O
is O
known O
regarding O
signal O
transduction O
events O
that O
occur O
after O
ligation O
of O
the O
T B
- I
cell I
antigen I
receptor I
( O
TCR B
) O
. O

In O
contrast O
, O
in O
vivo O
footprints O
on O
GT B
( I
CACCC I
) I
motifs I
differed O
between O
the O
cells O
expressing O
the O
fetal O
or O
the O
adult O
globin O
program O
. O

A O
cell B
type I
- I
specific I
enhancer I
in O
the O
human B
B7 I
. I
1 I
gene I
regulated O
by O
NF B
- I
kappaB I
. O

A O
cell B
type I
- I
specific I
enhancer I
in O
the O
human B
B7 I
. I
1 I
gene I
regulated O
by O
NF B
- I
kappaB I
. O

Analysis O
of O
its O
intron O
- O
exon O
structure O
has O
allowed O
identification O
of O
a O
C B
- I
terminal I
splice I
variant I
. O

One O
- O
hybrid O
assays O
in O
yeast B
isolated I
NF I
- I
ATp I
as O
an O
E1 B
binding I
protein I
, O
and O
transfection O
of O
NF B
- I
ATp I
into O
T O
and O
B O
cell O
lines O
strongly O
enhanced O
the O
activation B
- I
dependent I
SCM I
- I
1 I
promoter O
activity O
. O

Peptides O
derived O
from O
the O
HSV B
- I
2 I
VP16 I
protein I
were O
utilized O
for O
studies O
of O
peptide O
binding O
to O
DQ0302 O
molecules O
and O
T O
cell O
activation O
at O
both O
neutral O
and O
acidic O
pH O
. O

Administration O
of O
megakaryocyte B
growth I
and I
development I
factor I
or O
interleukin B
6 I
could O
not O
overcome O
the O
differentiation O
block O
. O

Inhibition O
of O
lipopolysaccharide O
- O
induced O
monocyte B
interleukin I
- I
1 I
receptor I
antagonist O
synthesis O
by O
cortisol O
: O
involvement O
of O
the O
mineralocorticoid B
receptor I
. O

Nuclear B
factor I
( I
NF I
) I
- I
kappa I
B I
is O
a O
redox B
sensitive I
cytosolic I
transcription I
factor I
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

Induction O
of O
endothelial B
adhesion I
molecules I
by O
the O
cytokine B
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
can O
occur O
independently O
of O
protein B
kinase I
C I
and O
activation O
of O
a O
protein B
tyrosine I
kinase I
( O
PTK B
) O
has O
recently O
been O
implicated O
in O
the O
upregulation O
of O
vascular B
cell I
adhesion I
molecule I
1 I
( O
VCAM B
- I
1 I
) O
by O
interleukin B
- I
4 I
( O
IL B
- I
4 I
) O
on O
endothelial O
cells O
. O

CD40 B
signaling O
activates O
downstream B
effectors I
, O
including O
the O
tyrosine B
protein I
kinase I
, O
Lyn B
, O
the O
phosphatidylinositol B
- I
3 I
- I
kinase I
( O
PI B
- I
3 I
kinase I
) O
, O
and O
the O
transcription O
factor O
, O
NF B
- I
kappa I
B I
. O

In O
this O
study O
, O
we O
demonstrate O
that O
stress B
- I
activated I
protein I
kinases I
( O
SAPK B
) O
are O
activated O
after O
CD40 B
cross O
- O
linking O
on O
various O
B O
cell O
lines O
or O
human O
tonsillar O
B O
cells O
. O

CD45 B
- O
dependent O
events O
such O
as O
tyrosine B
phosphorylation I
of O
Shc B
, O
activation O
of O
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
, O
activator B
protein I
- I
1 I
( O
AP B
- I
1 I
) O
, O
transcription B
factors I
, O
and O
stimulation O
of O
interleukin B
- I
2 I
( I
IL I
- I
2 I
) I
promoter I
and O
of O
CD69 B
and O
CD25 B
surface O
expression O
paralleled O
activation O
of O
the O
tyrosine B
kinases I
lck B
and O
fyn B
. O

9 O
- O
cis O
retinoic O
acid O
induces O
monocyte B
chemoattractant I
protein I
- I
1 I
secretion O
in O
human O
monocytic O
THP O
- O
1 O
cells O
. O

We O
have O
investigated O
mechanisms O
and O
consequences O
of O
STAT5 B
activation O
through O
the O
human B
IL I
- I
4 I
receptor I
( O
IL B
- I
4R I
) O
. O

By O
functionally O
expressing O
receptor B
mutants I
in O
the O
murine O
pro O
- O
B O
cell O
line O
Ba O
/ O
F3 O
, O
we O
could O
show O
that O
phosphorylated O
tyrosine O
residues O
within O
the O
IL B
- I
4R I
alpha I
chain I
are O
dispensable O
for O
IL B
- I
4 I
- O
induced O
STAT5 B
activity O
. O

An O
inhibitory O
, O
` O
` O
dominant O
- O
negative O
, O
' O
' O
form O
of O
the O
calcineurin B
catalytic I
( I
A I
) I
subunit I
was O
prepared O
, O
which O
lacks O
the O
calmodulin B
- I
binding I
domain I
, O
autoinhibitory B
domain I
and O
most O
of O
its O
catalytic O
core O
but O
possesses O
the O
regulatory B
( I
B I
) I
subunit I
binding O
domain O
. O

Monoclonal B
anti I
- I
D I
antibodies I
submitted O
to O
the O
Third O
Monoclonal O
International O
Workshop O
were O
evaluated O
against O
a O
number O
of O
D O
variant O
cells O
using O
standard O
serological O
techniques O
. O

Peroxisome B
proliferator I
- I
activated I
receptors I
( O
PPARs B
) O
, O
members O
of O
the O
nuclear B
receptor I
superfamily I
of O
transcription B
factors I
, O
are O
activated O
by O
fatty O
acid O
metabolites O
, O
peroxisome O
proliferators O
, O
and O
thiazolidinediones O
and O
are O
now O
recognized O
as O
important O
mediators O
in O
the O
inflammatory O
response O
. O

Eosinophil B
granule I
major I
basic I
protein I
( O
MBP B
) O
is O
expressed O
exclusively O
in O
eosinophils O
and O
basophils O
in O
hematopoietic O
cells O
. O

In O
summary O
, O
we O
have O
identified O
a O
tissue B
- I
specific I
regulatory I
region I
5 O
' O
of O
the O
ecto B
- I
5 I
' I
- I
NT I
core I
promoter I
that O
requires O
the O
presence O
of O
a O
functional O
CRE B
site I
within O
the O
basal B
promoter I
for O
its O
suppressive O
activity O
. O

( O
2 O
- O
Amino O
- O
3 O
' O
- O
methoxyphenyl O
) O
oxanaphthalen O
- O
4 O
- O
one O
( O
PD O
98059 O
) O
, O
an O
inhibitor O
of O
extracellular O
signal B
- I
regulated I
protein I
kinase I
( O
ERK B
) O
activation O
, O
blocked O
the O
serine O
phosphorylation O
of O
STAT3 B
induced O
by O
chemotactic B
factors I
or O
PMA O
. O

These O
bacterially B
- I
produced I
MR I
constructs I
had O
no O
steroid O
binding O
activity O
per O
se O
. O

We O
have O
shown O
that O
the O
c B
- I
Maf I
and O
c B
- I
Myb I
transcription I
factors I
physically O
interact O
in O
myeloid O
cells O
to O
form O
inhibitory O
complexes O
that O
hinder O
transactivation O
of O
c B
- I
Myb I
target I
genes I
through O
direct O
binding O
to O
Myb B
consensus I
sites I
. O

We O
have O
shown O
that O
the O
c B
- I
Maf I
and O
c B
- I
Myb I
transcription I
factors I
physically O
interact O
in O
myeloid O
cells O
to O
form O
inhibitory O
complexes O
that O
hinder O
transactivation O
of O
c B
- I
Myb I
target I
genes I
through O
direct O
binding O
to O
Myb B
consensus I
sites I
. O

To O
determine O
whether O
it O
is O
possible O
to O
artificially O
enhance O
the O
opening O
of O
the O
chromatin O
structure O
of O
a O
minimal B
beta I
- I
globin I
promoter I
, O
we O
placed O
a O
101bp O
, O
erythroid B
- I
specific I
DNase I
1 I
hypersensitive I
site I
- I
forming I
element I
( O
HSFE B
) O
immediately O
upstream O
of O
the O
beta B
- I
globin I
promoter I
and I
gene I
. O

However O
, O
the O
components O
of O
the O
NF B
- I
kappaB I
complexes I
were O
different O
in O
monocytes O
and O
B O
cells O
, O
because O
p50 B
is O
part O
of O
the O
NF B
- I
kappaB I
complex I
induced O
by O
CD40 B
triggering O
in O
both O
monocytes O
and O
B O
cells O
, O
whereas O
p65 B
was O
only O
induced O
in O
B O
cells O
. O
In O
contrast O
, O
although O
the O
Janus B
kinase I
3 I
tyrosine I
kinase I
was O
associated O
with O
CD40 B
molecules O
in O
both O
monocytes O
and O
resting O
B O
cells O
, O
Janus B
kinase I
3 I
phosphorylation O
induction O
was O
observed O
only O
in O
CD40 O
- O
activated O
monocytes O
, O
with O
subsequent O
induction O
of O
STAT5a B
DNA O
binding O
activity O
in O
the O
nucleus O
. O

Potent O
and O
stable O
attenuation O
of O
live O
- O
HIV O
- O
1 O
by O
gain O
of O
a O
proteolysis B
- I
resistant I
inhibitor I
of O
NF B
- I
kappaB I
( O
IkappaB B
- I
alphaS32 I
/ I
36A I
) O
and O
the O
implications O
for O
vaccine O
development O
. O

Regulation O
of O
Fas B
ligand I
expression O
and O
cell O
death O
by O
apoptosis B
- I
linked I
gene I
4 I
. O

Among O
upstream B
signaling I
molecules I
of O
ERK B
, O
Shc B
was O
constitutively O
associated O
with O
Grb2 O
and O
was O
not O
tyrosine O
- O
phosphorylated O
by O
GM B
- I
CSF I
and O
FMLP O
, O
and O
Sos1 B
and O
c B
- I
Raf I
- I
1 I
were O
not O
phosphorylated O
by O
GM B
- I
CSF I
, O
IL O
- O
3 O
, O
TNF O
, O
and O
FMLP O
in O
monocytes O
, O
whereas O
all O
these O
signaling O
molecules O
were O
affected O
and O
/ O
or O
utilized O
by O
GM B
- I
CSF I
in O
MO7e O
cells O
. O

Of O
even O
more O
interest O
, O
IkappaBalpha B
overexpression O
inhibited O
the O
production O
of O
matrix B
metalloproteinases I
1 I
and I
3 I
while O
not O
affecting O
their O
tissue O
inhibitor O
. O

Our O
results O
demonstrated O
that O
: O
( O
i O
) O
PGN O
induced O
phosphorylation O
of O
the O
transcription B
factors I
ATF B
- I
1 I
and O
CREB B
; O
( O
ii O
) O
ATF B
- I
1 I
and O
CREB B
bound O
DNA O
as O
a O
dimer O
and O
induced O
transcriptional O
activation O
of O
a O
CRE B
reporter I
plasmid I
, O
which O
was O
inhibited O
by O
dominant O
negative O
CREB B
and O
ATF B
- I
1 I
; O
( O
iii O
) O
PGN O
induced O
phosphorylation O
of O
c B
- I
Jun I
, O
protein O
synthesis O
of O
JunB B
and O
c B
- I
Fos I
, O
and O
transcriptional O
activation O
of O
the O
AP B
- I
1 I
reporter I
plasmid I
, O
which O
was O

In O
contrast O
, O
virus O
reactivation O
was O
not O
observed O
following O
CD4 B
oligomerization O
by O
antibodies B
that O
bind O
other O
epitopes O
in O
D1 B
, O
including O
the O
D1 B
/ I
CDR3 I
- I
loop I
. O

Our O
results O
indicate O
that O
the O
signaling O
events O
initiated O
in O
PBMCs O
by O
oligomerization O
of O
CD4 B
at O
the O
D1 B
/ I
CDR2 I
- I
loop I
can O
trigger O
HIV O
- O
1 O
upregulation O
in O
infected O
individuals O
. O

USF B
/ I
c I
- I
Myc I
enhances O
, O
while O
Yin B
- I
Yang I
1 I
suppresses O
, O
the O
promoter O
activity O
of O
CXCR4 B
, O
a O
coreceptor B
for O
HIV O
- O
1 O
entry O
. O

We O
have O
localized O
a O
317 O
base O
pair O
cis B
- I
acting I
regulatory I
element I
, O
HS B
I I
, O
associated O
with O
a O
hematopoietic B
- I
specific I
DNase I
I I
hypersensitive I
site I
, O
which O
lies O
approx O
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell B
cycle I
- I
related I
proteins I
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin B
- I
dependent I
kinase I
4 I
, O
cyclin B
D1 I
, O
and O
p53 B
, O
or O
expression O
of O
differentiation B
- I
related I
antigens I
. O

As2O3 O
induced O
PML O
( O
promyelocytic O
leukemia O
) O
protein O
degradation O
but O
did O
not O
modulate O
expression O
of O
cell B
cycle I
- I
related I
proteins I
, O
including O
c B
- I
myc I
, O
retinoblastoma B
protein I
, O
cyclin B
- I
dependent I
kinase I
4 I
, O
cyclin B
D1 I
, O
and O
p53 B
, O
or O
expression O
of O
differentiation B
- I
related I
antigens I
. O

A20 O
can O
be O
regulated O
by O
the O
NF B
- I
kappaB I
transcription B
factor I
, O
which O
is O
known O
to O
be O
activated O
by O
the O
EBV B
LMP I
- I
1 I
protein I
. O

Further O
, O
CTLA B
- I
4 I
engagement O
inhibited O
progression O
through O
the O
cell O
cycle O
by O
inhibiting O
the O
production O
of O
cyclin B
D3 I
, O
cyclin B
- I
dependent I
kinase I
( B
cdk I
) I
4 I
, O
and O
cdk6 B
when O
the O
T O
cells O
were O
stimulated O
with O
anti B
- I
CD3 I
/ I
CD28 I
and O
with O
anti B
- I
CD3 I
alone O
. O

PI B
3 I
- I
kinase I
also O
regulates O
the O
activity O
of O
p70 B
( I
s6k I
) I
, O
the O
40S B
ribosomal I
protein I
S6 I
kinase I
, O
a O
response O
that O
is O
abrogated O
by O
the O
macrolide O
rapamycin O
. O

These O
include O
the O
Ikaros B
, O
LKLF B
, O
and O
GATA3 B
zinc I
- I
finger I
proteins I
; O
the O
Ets B
, O
CREB B
/ I
ATF I
, O
and O
NF B
- I
kappa I
B I
/ I
Rel I
/ I
NFAT I
transcription I
factors I
; O
the O
Stat B
proteins I
; O
and O
HMG B
box I
transcription I
factors I
such O
as O
LEF1 B
, O
TCF1 B
, O
and O
Sox4 B
. O

Our O
previous O
studies O
pertaining O
to O
macrophage O
response O
to O
LPS O
identified O
a O
novel O
DNA B
- I
binding I
domain I
located O
from O
- O
550 O
to O
- O
487 O
in O
the O
human B
TNF I
- I
alpha I
promoter I
that O
contains O
transcriptional O
activity O
, O
but O
lacks O
any O
known O
NF B
- I
kappaB I
- B
binding I
sites I
. O

A O
human B
IFNGR1 I
small I
deletion I
hotspot I
associated O
with O
dominant O
susceptibility O
to O
mycobacterial O
infection O
[ O
see O
comments O
] O

These O
data O
indicated O
that O
two O
NF B
- I
kappaB I
- I
binding I
sites I
, O
which O
are O
located O
between O
- B
3134 I
and I
- I
3059 I
, O
are O
critical O
for O
the O
activation O
of O
proIL B
- I
1beta I
gene I
transcription O
. O

Gel O
supershift O
assays O
demonstrated O
that O
thrombin B
induced O
binding O
of O
NF B
- I
kappa I
Bp65 I
( O
Rel B
A I
) O
to O
downstream O
NF B
- I
kappa I
B I
site I
of O
the O
ICAM B
- I
1 I
promoter I
. O

These O
data O
indicate O
that O
thrombin B
activates O
endothelial O
ICAM B
- I
1 I
expression O
and O
polymorphonuclear O
leukocyte O
adhesion O
by O
NF B
- I
kappa I
Bp65 I
binding O
to O
the O
downstream O
NF B
- I
kappa I
B I
site I
of O
ICAM B
- I
1 I
promoter I
after O
proteolytically O
activated O
receptor O
- O
1 O
activation O
. O

RA O
previously O
was O
found O
to O
inhibit O
granulocyte B
colony I
- I
stimulating I
factor I
- O
- O
and O
not O
granulocyte B
- I
macrophage I
colony I
- I
stimulating I
factor I
- O
- O
stimulated O
proliferation O
of O
CD34 O
+ O
cells O
. O

Interestingly O
, O
CyA O
and O
indomethacin O
did O
not O
suppress O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
- I
alpha I
) O
- O
induced O
adhesion O
molecule O
expression O
on O
HUVECs O
, O
whereas O
aspirin O
had O
an O
inhibitory O
effect O
. O

A O
cdk2 O
inhibitor O
, O
Olomoucine O
, O
as O
well O
as O
a O
dominant B
- I
negative I
cdk2 I
construct I
prevented O
HLA B
class I
I I
- O
mediated O
inactivation O
of O
Rb B
; O
in O
contrast O
, O
dominant B
- I
negative I
cdk4 I
and I
cdk6 I
constructs I
had O
no O
effect O
. O

PG490 O
can O
completely O
inhibit O
transcriptional O
activation O
at O
the O
purine B
- I
box I
/ I
ARRE I
/ I
NF I
- I
AT I
and I
NF I
- I
kappaB I
target I
DNA I
sequences I
triggered O
by O
all O
stimuli O
examined O
( O
PMA O
, O
PMA O
/ O
Iono O
, O
tumor B
necrosis I
factor I
- I
alpha I
) O
. O

Most O
erythroleukemic O
cell O
lines O
established O
in O
vitro O
coexpress O
erythrocytic B
and I
megakaryocytic I
markers I
that O
often O
are O
associated O
with O
expression O
of O
Spi B
- I
1 I
and O
/ O
or O
Fli B
- I
1 I
transcription I
factors I
known O
as O
transactivators B
of I
megakaryocyte I
- I
specific I
promoters I
. O

However O
, O
like O
normal O
Ter O
119 O
erythroid O
cells O
, O
these O
Ter O
119 O
positive O
cells O
from O
transgenic O
mice O
still O
expressed O
high O
levels O
of O
beta B
- I
globin I
and O
very O
low O
or O
undetectable O
glycoprotein B
IIb I
and O
platelet B
factor I
4 I
megakaryocytic I
transcripts I
. O

SH2 B
domain I
- I
containing I
protein I
76 I
( O
SLP B
- I
76 I
) O
interacts O
with O
the O
guanine B
nucleotide I
exchange I
factor I
Vav B
to O
activate O
the O
nuclear B
factor I
of I
activated I
cells I
( O
NF B
- I
AT I
) O
, O
and O
its O
expression O
is O
required O
for O
normal O
T O
cell O
development O
. O

In O
contrast O
, O
another O
inducible O
gene O
expression O
of O
monocyte B
chemotactic I
protein I
- I
1 I
( O
a O
CC B
chemokine I
) O
and O
the O
activation O
of O
the O
transcriptional B
factor I
( O
FcRFgamma B
) O
bound O
to O
the O
gamma B
response I
region I
were O
similarly O
or O
less O
abundantly O
induced O
by O
IFNgamma B
treatment O
in O
PMA O
- O
or O
RA O
- O
differentiated O
U937 O
cells O
, O
indicating O
that O
increased O
IP B
- I
10 I
mRNA I
induction O
was O
not O
due O
to O
the O
augmented O
ability O
of O
the O
cells O
to O
respond O
to O
the O
presence O
of O
IFNgamma B
. O

In O
this O
report O
, O
we O
have O
analyzed O
the O
response O
of O
the O
hematopoietic O
precursor O
cell O
line O
32Dcl3 O
, O
expressing O
either O
the O
normal B
protein I
MDS1 I
/ I
EVI1 I
or O
the O
fusion B
protein I
AML1 I
/ I
MDS1 I
/ I
EVI1 I
, O
to O
factors O
that O
control O
cell O
differentiation O
or O
cell O
replication O
. O

By O
using O
the O
yeast O
two O
- O
hybrid O
system O
, O
we O
also O
show O
that O
EVI1 B
( O
contained O
in O
its O
entirety O
in O
MDS1 B
/ I
EVI1 I
and O
AML1 B
/ I
MDS1 I
/ I
EVI1 I
) O
physically O
interacts O
with O
SMAD3 B
, O
which O
is O
an O
intracellular O
mediator O
of O
TGF B
- I
beta1 I
signaling O
. O

The O
levels O
of O
cAMP B
- I
dependent I
protein I
kinase I
and O
Rap1 B
were O
assessed O
by O
Western O
blot O
analysis O
, O
immunostaining O
, O
and O
computer O
- O
assisted O
imaging O
. O

Tcf B
- I
1 I
- O
mediated O
transcription O
in O
T O
lymphocytes O
: O
differential O
role O
for O
glycogen B
synthase I
kinase I
- I
3 I
in O
fibroblasts O
and O
T O
cells O
. O

Expression O
of O
EBNA2 B
led O
to O
the O
transcriptional O
activation O
of O
both O
endogenous O
or O
transfected O
IFN B
- I
stimulated I
genes I
( O
ISGs B
) O
, O
genes O
which O
contain O
within O
their O
promoters B
either O
the O
interferon B
- I
stimulated I
response I
element I
( O
ISRE B
) O
or O
the O
gamma B
interferon I
activation I
site I
( O
GAS B
) O
. O

Detection O
of O
intracellular B
phosphorylated I
STAT I
- I
1 I
by O
flow O
cytometry O
. O

Glycoprotein B
( I
GP I
) I
IX I
is O
a O
subunit O
of O
the O
von B
Willebrand I
receptor I
, O
GPIb B
- I
V I
- I
IX I
, O
which O
mediates O
adhesion O
of O
platelets O
to O
the O
subendothelium O
of O
damaged O
blood O
vessels O
. O

Glycoprotein B
( I
GP I
) I
IX I
is O
a O
subunit O
of O
the O
von B
Willebrand I
receptor I
, O
GPIb B
- I
V I
- I
IX I
, O
which O
mediates O
adhesion O
of O
platelets O
to O
the O
subendothelium O
of O
damaged O
blood O
vessels O
. O

Additionally O
, O
CoCl2 O
caused O
a O
two O
- O
to O
threefold O
increase O
in O
the O
rate O
of O
transendothelial O
migration O
of O
monocyte O
- O
like O
HL O
- O
60 O
cells O
and O
a O
twentyfold O
increase O
in O
phosphorylation O
of O
platelet B
endothelial I
cell I
adhesion I
molecules I
( O
PECAM B
- I
1 I
) O
. O

Furthermore O
, O
the O
two O
VDR B
3 I
' I
- I
UTR I
haplotypes O
conferred O
an O
identical O
half O
- O
life O
on O
a O
heterologous B
beta I
- I
globin I
reporter I
gene I
, O
in O
an O
in O
vitro O
assay O
. O

Binding O
of O
HMG B
- I
I I
( I
Y I
) I
elicits O
structural O
changes O
in O
a O
silencer O
of O
the O
human B
beta I
- I
globin I
gene I
. O

In O
order O
to O
elucidate O
the O
role O
of O
NF B
- I
ATp I
, O
one O
of O
the O
most O
prominent O
members O
of O
family O
of O
NF B
- I
AT I
transcription I
factors I
in O
peripheral O
T O
lymphocytes O
, O
in O
T O
cell O
activation O
and O
differentiation O
we O
created O
NF B
- I
ATp I
- O
deficient O
mice O
by O
gene O
targeting O
. O

FasL B
- I
dependent I
reporter I
constructs I
in O
MRL O
- O
lpr O
/ O
lpr O
and O
C3H O
- O
gld O
/ O
gld O
CD4 O
( O
- O
) O
CD8 O
( O
- O
) O
T O
cells O
were O
constitutively O
active O
, O
and O
this O
activity O
was O
largely O
prevented O
by O
mutation O
of O
the O
critical O
Egr B
family I
binding I
element I
. O

The O
functional O
contribution O
of O
the O
kappaB B
- I
Sp1 I
composite I
site I
in O
P B
/ I
I I
- I
inducible I
fas I
promoter I
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- B
295 I
to I
- I
286 I
) O
in O
a O
thymidine B
kinase I
promoter I
- I
driven I
reporter I
construct I
and O
native B
promoter I
constructs I
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

The O
functional O
contribution O
of O
the O
kappaB B
- I
Sp1 I
composite I
site I
in O
P B
/ I
I I
- I
inducible I
fas I
promoter I
activation O
was O
verified O
by O
using O
kappaB O
- O
Sp1 B
concatamers O
( O
- B
295 I
to I
- I
286 I
) O
in O
a O
thymidine B
kinase I
promoter I
- I
driven I
reporter I
construct I
and O
native B
promoter I
constructs I
in O
Jurkat O
cells O
overexpressing O
IkappaB B
- I
alpha I
. O

We O
have O
mapped O
the O
DNase B
- I
I I
- I
hypersensitive I
( I
HS I
) I
regions I
of O
the O
human B
GATA I
- I
3 I
gene I
in O
T O
- O
cells O
and O
non O
- O
T O
- O
cells O
and O
studied O
their O
transcriptional O
activities O
. O

However O
, O
both O
pathways O
were O
necessary O
for O
another O
transformation O
- O
related O
activity O
( O
colony O
formation O
in O
soft O
agar O
) O
of O
CTLL B
- I
2 I
/ I
Tax I
. O

These O
findings O
suggest O
that O
high O
- O
level O
IL B
- I
4 I
production O
in O
atopic O
Th2 O
cells O
is O
associated O
with O
selective O
reduction O
of O
suppressive O
NFAT1 B
activity O
at O
the O
IL B
- I
4 I
P0 I
element I
and O
that O
some O
patients O
with O
this O
multifactorial O
disease O
may O
have O
a O
putative O
systemic O
disorder O
at O
this O
level O
. O

A O
role O
for O
changes O
in O
immunophilins B
, O
causing O
glucocorticoid O
resistance O
in O
neotropical O
primates O
, O
is O
supported O
by O
the O
following O
: O
the O
changes O
in O
FKBP51 B
and O
FKBP52 B
were O
observed O
in O
cells O
from O
other O
neotropical O
primates O
with O
glucocorticoid O
resistance O
; O
the O
elevated O
level O
of O
FKBP51 B
was O
reflected O
in O
an O
abundance O
of O
FKBP51 B
in O
heat B
shock I
protein I
90 I
complexes I
in O
SML O
; O
when O
cytosols O
of O
SML O
and O
L929 O
cells O
were O
mixed O
, O
the O
decrease O
in O
GR O
binding O
was O
associated O
with O
incorporation O
of O
FKBP51 B
into O

This O
pro B
- I
IL I
- I
16 I
is O
subsequently O
processed O
to O
the O
mature O
cytokine O
of O
13 B
kDa I
. O

The O
Megakaryocyte B
/ I
Platelet I
- I
specific I
enhancer I
of O
the O
alpha2beta1 B
integrin I
gene I
: O
two O
tandem O
AP1 B
sites I
and O
the O
mitogen B
- I
activated I
protein I
kinase I
signaling O
cascade O
. O

Therefore O
, O
our O
data O
not O
only O
reveal O
that O
Nmi B
can O
potentiate O
STAT B
- O
dependent O
transcription O
, O
but O
also O
suggest O
that O
it O
can O
augment O
coactivator O
protein O
recruitment O
to O
at O
least O
some O
members O
of O
a O
group O
of O
sequence B
- I
specific I
transcription I
factors I
. O

These O
agents O
also O
significantly O
decreased O
TNF B
- O
and O
LPS O
- O
stimulated O
increases O
in O
HUVEC B
surface I
VCAM I
- I
1 I
. O

TNF B
stimulated O
expression O
of O
both O
intercellular B
adhesion I
molecule I
- I
1 I
and O
E B
- I
selectin I
in O
HUVECs O
, O
but O
in O
HUAECs O
, O
only O
intercellular B
adhesion I
molecule I
- I
1 I
was O
increased O
. O

TNF B
stimulated O
expression O
of O
both O
intercellular B
adhesion I
molecule I
- I
1 I
and O
E B
- I
selectin I
in O
HUVECs O
, O
but O
in O
HUAECs O
, O
only O
intercellular B
adhesion I
molecule I
- I
1 I
was O
increased O
. O

IL B
- I
10 I
preincubation O
resulted O
in O
the O
inhibition O
of O
gene O
expression O
for O
several O
IFN B
- I
induced I
genes I
, O
such O
as O
IP B
- I
10 I
, O
ISG54 B
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

We O
incubated O
sodium O
oleate O
with O
human O
umbilical O
vein O
endothelial O
cells O
for O
0 O
to O
72 O
hours O
, O
followed O
by O
coincubation O
of O
oleate O
with O
human B
recombinant I
tumor I
necrosis I
factor I
, O
interleukin B
( I
IL I
) I
- I
1alpha I
, O
IL B
- I
1beta I
, O
IL B
- I
4 I
, O
Escherichia O
coli O
lipopolysaccharide O
( O
LPS O
) O
, O
or O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
for O
a O
further O
6 O
to O
24 O
hours O
. O

The O
endothelial O
expression O
of O
vascular B
cell I
adhesion I
molecule I
- I
1 I
( O
VCAM B
- I
1 I
) O
, O
E B
- I
selectin I
, O
and O
intercellular B
adhesion I
molecule I
- I
1 I
was O
monitored O
by O
cell O
surface O
enzyme O
immunoassays O
or O
flow O
cytometry O
, O
and O
steady O
- O
state O
levels O
of O
VCAM B
- I
1 I
mRNA I
were O
assessed O
by O
Northern O
blot O
analysis O
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS B
/ I
FLI I
- I
1 I
fusion I
protein I
and O
from O
mutated B
K I
- I
RAS I
protein I
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position B
12 I
) O
that O
showed O
binding B
motif I
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

RESULTS O
: O
We O
identified O
peptides O
derived O
from O
EWS B
/ I
FLI I
- I
1 I
fusion I
protein I
and O
from O
mutated B
K I
- I
RAS I
protein I
( O
encompassing O
respectively O
the O
fusion B
point I
and O
the O
mutation O
at O
position B
12 I
) O
that O
showed O
binding B
motif I
for O
HLA B
- I
Cw I
* I
0702 I
and O
HLA B
- I
A3 I
respectively O
. O

OCA B
- I
B I
is O
a O
functional O
analog O
of O
VP16 B
but O
targets O
a O
separate O
surface O
of O
the O
Oct B
- I
1 I
POU I
domain I
[ O
published O
erratum O
appears O
in O
Mol O
Cell O
Biol O
1998 O
Apr O
; O
18 O
( O
4 O
) O
: O
2430 O
] O

These O
results O
emphasize O
the O
structural O
versatility O
of O
the O
Oct B
- I
1 I
POU I
domain I
in O
its O
interaction O
with O
coregulators O
. O

This O
induction O
of O
C B
/ I
EBP I
epsilon I
mRNA I
expression O
is O
transcriptionally O
mediated O
and O
occurs O
in O
the O
absence O
of O
synthesis O
of O
additional O
protein B
factors I
. O

We O
suspect O
that O
the O
C B
/ I
EBP I
epsilon I
promoter I
/ I
enhancer I
contains O
a O
retinoic B
acid I
- I
response I
element I
that O
is O
directly O
stimulated O
by O
retinoids O
. O

Transfection O
of O
EL O
- O
4 O
cells O
with O
the O
IL B
- I
4 I
promoter I
- I
reporter I
constructs I
carrying O
mutated B
P I
- I
like I
elements I
showed O
that O
four O
P B
- I
like I
elements I
, O
CLE0 B
, O
P B
, O
P2 B
and O
P4 B
, O
but O
not O
P3 B
, O
were O
required O
for O
optimal O
activation O
of O
the O
IL B
- I
4 I
promoter I
. O

The O
initiating O
event O
is O
still O
uncertain O
, O
but O
activation O
of O
a O
recently O
described O
receptor B
- I
associated I
protein I
kinase I
is O
one O
of O
the O
earliest O
events O
detectable O
( O
Martin O
et O
al O
. O
, O
Eur O
. O
J O
. O
Immunol O
. O
1994 O
. O
24 O
: O
1566 O
) O
. O

The O
A B
- I
myb I
transcription I
factor I
in O
neoplastic O
and O
normal O
B O
cells O
. O

We O
recently O
identified O
the O
winged B
- I
helix I
transcription I
factor I
Trident B
and O
described O
its O
expression O
pattern O
in O
synchronized O
fibroblasts O
. O

Furthermore O
, O
compared O
with O
wild B
- I
type I
Id3 I
, O
an O
Id3 B
Asp5 I
mutant I
( O
mimicking O
phosphorylation O
) O
is O
unable O
to O
promote O
cell O
cycle O
S O
phase O
entry O
in O
transfected O
fibroblasts O
, O
whereas O
an O
Id3 B
Ala5 I
mutant I
( O
ablating O
phosphorylation O
) O
displays O
an O
activity O
significantly O
greater O
than O
that O
of O
wild B
- I
type I
Id3 I
protein I
. O

These O
data O
indicate O
that O
the O
TRE B
- I
like I
cAMP I
- I
responsive I
DSE I
sites I
within O
the O
5 B
' I
- I
untranslated I
leader I
can O
mediate O
the O
transcriptional O
cooperativity O
between O
TNFalpha B
and O
the O
cAMP O
/ B
PKA I
pathway O
. O

Mutation O
of O
the O
CBF1 B
/ I
RBP I
- I
Jkappa I
binding I
site I
in O
EBNA3C B
abrogated O
repression O
, O
strongly O
suggesting O
that O
CBF1 B
/ I
RBP I
- I
Jkappa I
is O
necessary O
for O
targeting O
the O
viral O
protein O
to O
Cp B
. O

Cooperation O
of O
binding B
sites I
for O
STAT6 B
and O
NF B
kappa I
B I
/ I
rel I
in O
the O
IL B
- I
4 I
- O
induced O
up O
- O
regulation O
of O
the O
human B
IgE I
germline I
promoter I
. O

Stable O
transfection O
of O
U937 O
cells O
with O
sense O
or O
antisense B
RXR I
- I
alpha I
cDNA I
suggests O
a O
role O
for O
RXR B
- I
alpha I
in O
the O
control O
of O
monoblastic O
differentiation O
induced O
by O
retinoic O
acid O
and O
vitamin O
D O
. O

Furthermore O
, O
deletion O
and O
mutation O
analyses O
of O
the O
VCAM B
- I
1 I
promoter I
performed O
with O
chloramphenicol B
acetyltransferase I
constructs I
revealed O
that O
Tax B
was O
trans O
activating O
the O
VCAM B
- I
1 I
promoter I
via O
two O
NF B
- I
kappaB I
sites I
present O
at O
bp O
- O
72 O
and O
- O
57 O
in O
the O
VCAM B
- I
1 I
gene I
promoter I
, O
with O
both O
of O
them O
being O
required O
for O
the O
Tax B
- O
induced O
expression O
of O
this O
adhesion B
molecule I
. O

IL B
- I
2 I
and O
T B
cell I
antigen I
receptor I
complex I
induction O
of O
STAT3alpha B
serine O
727 O
phosphorylation O
is O
dependent O
on O
the O
activity O
of O
the O
MEK B
/ B
ERK I
pathway O
. O

The O
composite B
PU I
. I
1 I
and I
Pip I
site I
likely O
accounts O
for O
both O
lineage O
and O
stage O
- O
specific O
expression O
of O
CD20 B
whereas O
the O
CD20 B
E I
box I
binding I
proteins I
enhance O
overall O
promoter O
activity O
and O
may O
link O
the O
promoter O
to O
a O
distant B
enhancer I
. O

Control O
of O
NF B
- I
kappa I
B I
activity O
by O
the O
I B
kappa I
B I
beta I
inhibitor I
. O

Interleukin B
- I
7 I
upregulates O
the O
interleukin B
- I
2 I
- I
gene I
expression O
in O
activated O
human O
T O
lymphocytes O
at O
the O
transcriptional O
level O
by O
enhancing O
the O
DNA O
binding O
activities O
of O
both O
nuclear O
factor O
of O
activated O
T O
cells O
and O
activator B
protein I
- I
1 I
. O

Production O
of O
IL B
- I
2 I
requires O
the O
formation O
of O
transcription B
factors I
involved O
in O
the O
IL B
- I
2 I
- I
gene I
regulation O
. O

The O
three O
- O
dimensional O
positioning O
of O
immunoglobulin B
( I
Ig I
) I
genes I
within O
the O
nucleus O
of O
human O
cells O
was O
investigated O
using O
in O
situ O
hybridization O
and O
confocal O
microscopy O
. O

The O
visualization O
of O
heavy B
and I
light I
chain I
genes I
in O
B O
- O
lymphoid O
cells O
showed O
that O
the O
three O
Ig B
genes I
are O
differentially O
and O
nonrandomly O
distributed O
in O
different O
nuclear O
subvolumes O
: O
the O
kappa B
genes I
were O
found O
to O
be O
preferentially O
confined O
to O
an O
outer O
nuclear O
volume O
, O
whereas O
the O
gamma B
and I
lambda I
genes I
consistently O
occupied O
more O
central O
positions O
within O
the O
nucleus O
, O
the O
lambda B
genes I
being O
more O
interior O
when O
compared O
with O
the O
gamma B
genes I
. O

Induction O
of O
endothelial B
cell I
surface I
adhesion I
molecules I
by O
tumor B
necrosis I
factor I
is O
blocked O
by O
protein O
tyrosine O
phosphatase O
inhibitors O
: O
role O
of O
the O
nuclear B
transcription I
factor I
NF I
- I
kappa I
B I
. O

In O
contrast O
, O
I B
kappa I
B I
- I
alpha I
levels O
in O
PBMC O
and O
monocytes O
from O
healthy O
subjects O
or O
from O
patients O
with O
nontuberculous O
pulmonary O
conditions O
were O
intact O
. O

Further O
, O
M O
. O
tuberculosis O
and O
its O
tuberculin B
, O
purified B
protein I
derivative I
, O
induced O
the O
degradation O
of O
I B
kappa I
B I
- I
alpha I
and O
the O
expression O
of O
I B
kappa I
B I
- I
alpha I
mRNA I
, O
and O
purified O
protein O
derivative O
induced O
the O
activation O
of O
NF B
- I
kappa I
B I
in O
monocytes O
. O

As O
shown O
by O
reverse O
transcription O
- O
polymerase O
chain O
reaction O
and O
electrophoretic O
mobility O
shift O
assay O
, O
respectively O
, O
treatment O
with O
CsA O
leads O
to O
decreased O
TF B
mRNA I
expression O
and O
reduced O
activation O
of O
the O
NF B
- I
kappaB I
transcription I
factor I
, O
which O
is O
known O
to O
contribute O
to O
the O
induction O
of O
the O
TF B
promotor I
in O
human O
monocytes O
. O

Both O
cytokines B
induced O
assembly O
of O
STAT5A B
and O
STAT5B B
containing O
complexes O
capable O
of O
binding O
to O
the O
interferon B
- I
gamma I
activation I
sequence I
( O
GAS B
) O
, O
and O
these O
complexes O
rapidly O
translocated O
( O
within O
1 O
min O
) O
into O
the O
nucleus O
of O
IL O
- O
2 O
- O
or O
IL O
- O
7 O
- O
treated O
cells O
. O

The O
class B
II I
trans I
- I
activator I
( O
CIITA B
) O
is O
a O
bi B
- I
or I
multi I
- I
functional I
domain I
protein I
which O
plays O
a O
critical O
role O
in O
the O
expression O
of O
MHC B
class I
II I
genes I
. O

NF B
- I
AT I
activation O
induced O
by O
a O
CAML B
- O
interacting O
member O
of O
the O
tumor B
necrosis I
factor I
receptor I
superfamily I
. O

Proteins O
of O
the O
ATF O
/ O
CREB B
class O
of O
transcription B
factors I
stimulate O
gene O
expression O
of O
several O
cell B
growth I
- I
related I
genes I
through O
protein B
kinase I
A I
- I
related I
cAMP I
response I
elements I
. O

Thus O
, O
our O
data O
establish O
that O
ATF B
/ I
CREB I
factors I
functionally O
modulate O
histone B
H4 I
gene I
transcription O
at O
distal B
and I
proximal I
promoter I
elements I
. O

Using O
a O
radiolabeled O
chemical O
probe O
, O
we O
here O
purified O
a O
target O
of O
SR O
31747A O
and O
called O
it O
SR B
31747A I
- I
binding I
protein I
( O
SR B
- I
BP I
) O
. O

Purified B
SR I
- I
BP I
retained O
its O
binding O
properties O
and O
migrated O
on O
SDS O
- O
polyacrylamide O
gel O
as O
a O
Mr B
28 I
, I
000 I
protein I
. O

Moreover O
, O
anti B
- I
TNF I
- I
alpha I
inhibited O
HIV B
- I
1 I
long I
terminal I
repeat I
( O
LTR B
) O
- O
driven O
transcription O
of O
a O
reporter B
gene I
in O
primary O
T O
cells O
in O
response O
to O
activation O
, O
either O
in O
the O
presence O
or O
the O
absence O
of O
HIV B
- I
1 I
Tat I
. O

Our O
results O
demonstrate O
that O
short O
- O
term O
incubation O
of O
these O
cells O
with O
oxLDL B
activated I
p50 I
/ I
p65 I
containing O
NF B
- I
kappa I
B I
dimers I
and O
induced O
the O
expression O
of O
the O
target B
gene I
IL I
- I
8 I
. O

Our O
results O
demonstrate O
that O
short O
- O
term O
incubation O
of O
these O
cells O
with O
oxLDL B
activated I
p50 I
/ I
p65 I
containing O
NF B
- I
kappa I
B I
dimers I
and O
induced O
the O
expression O
of O
the O
target B
gene I
IL I
- I
8 I
. O

Our O
results O
demonstrate O
that O
short O
- O
term O
incubation O
of O
these O
cells O
with O
oxLDL B
activated I
p50 I
/ I
p65 I
containing O
NF B
- I
kappa I
B I
dimers I
and O
induced O
the O
expression O
of O
the O
target B
gene I
IL I
- I
8 I
. O

The O
oxLDL B
- O
induced O
NF B
- I
kappa I
B I
activation O
was O
accompanied O
by O
an O
initial O
depletion O
of O
I B
kappa I
B I
- I
alpha I
followed O
by O
a O
slight O
transient O
increase O
in O
the O
level O
of O
this O
inhibitor O
protein O
. O

Eotaxin B
is O
an O
eosinophil B
specific I
beta I
- I
chemokine I
assumed O
to O
be O
involved O
in O
eosinophilic O
inflammatory O
diseases O
such O
as O
atopic O
dermatitis O
, O
allergic O
rhinitis O
, O
asthma O
and O
parasitic O
infections O
. O

The O
pp52 B
promoter I
contains O
an O
initiator O
specifying O
the O
unique O
5 B
' I
terminus I
of O
pp52 B
mRNA I
, O
tandem O
pairs O
of O
Ets B
and I
SP1 I
motifs I
, O
and O
a O
lone B
C I
/ I
EBP I
motif I
. O

BACKGROUND O
: O
Recent O
studies O
have O
raised O
the O
hypothesis O
that O
glucocorticoids O
could O
diminish O
the O
ability O
of O
endothelial O
cells O
to O
direct O
leukocyte O
traffic O
into O
inflamed O
tissues O
by O
inhibiting O
expression O
of O
the O
adhesion B
molecules I
endothelial B
- I
leukocyte I
adhesion I
molecule I
- I
1 I
and O
intercellular B
adhesion I
molecule I
- I
1 I
. O

In O
a O
previous O
study O
, O
we O
demonstrated O
that O
bufalin O
, O
which O
is O
an O
active O
principle O
of O
Chinese O
medicine O
, O
chan O
' O
su O
, O
caused O
apoptosis O
in O
human O
leukemia O
U937 O
cells O
by O
anomalous O
activation O
of O
mitogen B
- I
activated I
protein I
kinase I
( O
MAPK B
) O
via O
the O
signaling O
pathway O
of O
Ras B
, O
Raf B
- I
1 I
, O
and O
MAPK B
kinase I
- I
1 I
. O

We O
report O
the O
identification O
and O
characterization O
of O
simple B
tandem I
repeat I
DNA I
polymorphisms I
in O
the O
genes O
encoding O
HNF B
- I
3alpha I
, O
- B
3beta I
, O
- B
3gamma I
, O
- B
4gamma I
, O
and O
- B
6 I
and O
the O
mapping O
of O
HNF B
- I
6 I
to O
chromosome B
bands I
15q21 B
. I
1 I
- I
21 I
. I
2 I
by O
fluorescence O
in O
situ O
hybridization O
. O

In O
THP O
- O
1 O
cells O
transfected O
with O
HIV B
plasmid I
constructs I
, O
both O
organisms O
induced O
transcription O
from O
the O
HIV B
long I
terminal I
repeat I
that O
was O
dependent O
on O
intact O
NF B
- I
kappaB I
binding I
sequences I
. O

In O
these O
cells O
, O
Stat6 B
activation O
led O
to O
the O
induction O
of O
the O
beta B
- I
casein I
gene I
promoter I
. O

Additional O
major O
protein O
- O
DNA O
interactions O
do O
not O
occur O
within O
the O
promoter O
region O
after O
T O
lymphocyte O
activation O
, O
indicating O
a O
requirement O
for O
additional O
protein O
- O
protein O
interactions O
and O
/ O
or O
post O
- O
translational O
modifications O
of O
pre B
- I
bound I
transcription I
factors I
to O
account O
for O
the O
observed O
increase O
in O
IMPDH O
type O
II O
gene O
expression O
. O

The O
human B
C I
/ I
EBPepsilon I
gene I
is O
transcribed O
by O
two O
alternative O
promoters B
, O
Palpha B
and O
Pbeta B
. O

Furthermore O
, O
increasing O
the O
spacing O
between O
the O
CRE B
and I
the I
kappaB3 I
sites I
completely O
abolished O
LPS O
induction O
, O
suggesting O
a O
cooperative O
interaction O
between O
c B
- I
Jun I
complexes I
and O
p50 B
/ I
p65 I
. O

IFN B
- I
alpha I
/ I
beta I
specifically O
induced O
tyrosine O
phosphorylation O
and O
translocation O
into O
nucleus O
of O
signal B
transducers I
and I
activators I
of I
transcription I
( I
STAT I
) I
2 I
protein I
in O
the O
T O
cell O
clones O
. O

IL B
- I
10 I
inhibition O
of O
IFN B
- I
gamma I
- O
induced O
ICAM B
- I
1 I
expression O
was O
apparent O
as O
early O
as O
3 O
hours O
and O
was O
blocked O
by O
an O
anti B
- I
IL I
- I
10 I
antibody I
but O
not O
by O
an O
isotype B
- I
matched I
control I
antibody I
. O

The O
resulting O
fusion B
genes I
encode O
the O
two O
structurally O
unique O
PML B
/ I
RARalpha I
and O
RARalpha B
/ I
PML I
fusion I
proteins I
as O
well O
as O
aberrant B
PML I
gene I
products I
, O
the O
respective O
pathogenetic O
roles O
of O
which O
have O
not O
been O
elucidated O
. O

This O
novel B
target I
site I
, O
denoted O
the O
C B
- I
site I
, O
was O
shown O
by O
several O
criteria O
, O
including O
cell O
distribution O
studies O
, O
stimulation O
experiments O
, O
supershift O
assays O
, O
and O
cross O
- O
competition O
electrophoretic O
mobility O
shift O
assays O
to O
bind O
the O
transcription B
factor I
AP I
- I
1 I
. O

The O
involvement O
of O
the O
CCK B
( I
B I
) I
receptor I
in O
such O
a O
stimulation O
was O
demonstrated O
by O
the O
inhibiting O
effect O
of O
the O
selective O
CCK B
( I
B I
) I
receptor I
antagonist O
PD O
- O
135 O
, O
158 O
. O

The O
involvement O
of O
the O
CCK B
( I
B I
) I
receptor I
in O
such O
a O
stimulation O
was O
demonstrated O
by O
the O
inhibiting O
effect O
of O
the O
selective O
CCK B
( I
B I
) I
receptor I
antagonist O
PD O
- O
135 O
, O
158 O
. O

Our O
results O
indicate O
that O
CCK O
- O
8 O
exerts O
a O
trophic O
effect O
in O
Jurkat O
T O
cells O
through O
stimulation O
of O
CCK B
( I
B I
) I
receptors I
by O
modulation O
of O
expression O
of O
AP B
- I
1 I
- I
regulated I
genes I
. O

In O
fact O
, O
the O
offspring O
of O
alcoholics O
have O
higher O
levels O
of O
G B
( I
S I
) I
alpha I
expression O
in O
certain O
tissues O
compared O
with O
the O
offspring O
of O
nonalcoholics O
. O

The O
aim O
of O
this O
research O
was O
to O
test O
the O
hypothesis O
that O
a O
causal O
relationship O
exists O
between O
the O
level O
of O
expression O
of O
G B
( I
S I
) I
alpha I
and O
induction O
of O
the O
adenylyl B
cyclase I
( O
AC O
) O
cascade O
. O

The O
methodology O
employed O
transient O
transfection O
of O
HEK O
293 O
cells O
with O
a O
cDNA O
for O
the O
52 O
- O
kDa O
form O
of O
G B
( I
S I
) I
alpha I
under O
regulation O
by O
inducible B
metallothionein I
promoters I
. O

Patients O
with O
one O
type O
of O
major B
histocompatibility I
complex I
class I
II I
combined O
immunodeficiency O
have O
mutations O
in O
a O
gene O
termed O
class B
II I
transactivator I
( O
CIITA B
) O
, O
which O
coordinately O
controls O
the O
transcription O
of O
the O
three O
major O
human B
class I
II I
genes I
, O
HLA B
- I
DR I
, I
- I
DQ I
, I
and I
- I
DP I
. O

Characterization O
of O
peripheral O
blood O
T O
- O
lymphocytes O
transduced O
with O
HTLV B
- I
I I
Tax I
mutants I
with O
different O
trans O
- O
activating O
phenotypes O
. O

Altogether O
, O
our O
data O
demonstrate O
that O
: O
( O
a O
) O
the O
ability O
of O
B O
cells O
to O
release O
TNF B
- I
alpha I
after O
triggering O
of O
HLA B
- I
DR I
antigens I
depends O
on O
their O
stage O
of O
differentiation O
; O
( O
b O
) O
levels O
of O
released O
TNF B
- I
alpha I
seem O
to O
correlate O
with O
the O
stage O
of O
B O
- O
cell O
maturation O
but O
do O
not O
correlate O
with O
the O
amounts O
of O
cell B
surface I
HLA I
- I
DR I
antigens I
; O
( O
c O
) O
secreted O
TNF B
- I
alpha I
regulates O
the O
levels O
of O
expression O
of O
NF B
- I
kappa I
B I
and O
AP B
- I
1 I
by O
an O
autocrine O
loop O
; O
and O
( O
d O
) O
intracellular O
signals O
mediating O

The O
predictive B
protein I
- I
coding I
region I
of O
RP1 B
had O
a O
significant O
homology O
to O
members O
of O
the O
recently O
found O
adenomatous B
polyposis I
coli I
( I
APC I
) I
protein I
- I
binding I
EB1 I
gene I
family I
, O
which O
codes O
for O
yet O
unknown O
protein O
( O
s O
) O
. O

Collectively O
, O
these O
findings O
indicate O
that O
NF B
- I
kappa I
B I
activation O
might O
constitute O
one O
of O
the O
mechanisms O
underlying O
the O
inducible O
expression O
of O
kappa B
B I
- I
dependent I
genes I
in O
microglia O
stimulated O
by O
A O
beta O
peptides O
and O
IFN B
gamma I
, O
or O
by O
LPS O
. O

Chloramphenicol B
acetyltransferase I
expression I
constructs I
containing O
regions O
of O
the O
human B
collagenase I
- I
1 I
promoter I
were O
stably O
or O
transiently O
transfected O
into O
U937 O
cells O
, O
and O
reporter O
activity O
was O
assessed O
at O
various O
times O
after O
the O
onset O
of O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
- O
mediated O
differentiation O
. O

In O
particular O
, O
Western O
, O
supershift O
, O
and O
promoter O
deletion O
analyses O
suggested O
a O
role O
for O
CCAAT B
/ I
enhancer I
- I
binding I
protein I
- I
beta I
( I
C I
/ I
EBP I
- I
beta I
) I
binding I
site I
between O
- B
2010 I
and I
- I
1954 I
in O
regulating O
transcription O
of O
collagenase B
- I
1 I
in O
monocytic O
cells O
. O

Both O
truncated O
forms O
also O
bound O
to O
the O
transcription B
factor I
RBP I
- I
Jkappa I
in O
extracts O
prepared O
from O
human O
and O
murine O
T O
- O
ALL O
cell O
lines O
. O

c B
- I
Fos I
protein O
was O
shown O
essential O
for O
an O
optimal O
transactivation O
of O
the O
HIV O
- O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
by O
Tat B
: O
incubation O
of O
Jurkat O
cells O
with O
antisense O
, O
but O
not O
sense O
, O
c O
- O
fos O
oligonucleotides O
significantly O
reduced O
either O
the O
Tat B
- O
enhanced O
expression O
of O
an O
LTR B
- I
CAT I
reporter I
construct I
or O
the O
levels O
of O
gag B
p24 I
in O
the O
culture O
supernatants O
of O
Jurkat O
cells O
and O
PBMC O
acutely O
infected O
with O
HIV O
- O
1 O
. O

The O
human B
TF I
promoter I
contains O
binding O
sites O
for O
the O
transcription O
factors O
AP B
- I
1 I
, O
c B
- I
Rel I
/ I
p65 I
, O
Egr B
- I
1 I
, O
and O
Sp1 B
. O

Immunoblot O
and O
flow O
cytometry O
analysis O
revealed O
a O
limited O
proteolysis O
of O
the O
carboxyl B
terminus I
of O
the O
alphaIIb B
subunit I
heavy I
chain I
( O
alphaIIbH B
) O
, O
as O
judged O
by O
the O
disappearance O
of O
the O
epitope O
for O
the O
monoclonal B
antibody I
PMI I
- I
1 I
. O

Redox O
regulation O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
during O
lymphocyte O
activation O
. O

However O
, O
NF B
- I
YB I
did O
interact O
with O
the O
C B
- I
terminal I
Tax1 I
mutants I
M22 B
( O
130TL B
- I
AS I
) O
and O
M47 B
( O
319LL B
- I
RS I
) O
. O

CONCLUSION O
: O
These O
studies O
suggest O
that O
RA O
can O
augment O
IL B
- I
2 I
mRNA I
production O
by O
T O
cells O
with O
a O
possible O
paracrine O
effect O
on O
IL B
- I
2R I
- I
alpha I
expression O
. O

In O
contrast O
, O
the O
RelA B
( I
p65 I
) I
subunit I
was O
barely O
detectable O
in O
monocytes O
, O
but O
its O
level O
increased O
markedly O
in O
MDMs O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Using O
anti B
- I
C I
/ I
EBPbeta I
( O
NF B
- I
IL6 I
) O
, O
anti B
- I
C I
/ I
EBPdelta I
( O
NF B
- I
IL6beta I
) O
, O
anti B
- I
NF I
- I
ATc I
, O
anti B
- I
NF I
- I
ATp I
, O
anti B
- I
Fos I
, O
and O
anti B
- I
Jun I
Abs I
we O
demonstrate O
that O
the O
previously O
identified O
PRE B
- I
I I
binding I
factor I
POS B
- I
1 I
is O
composed O
of O
different O
transcription B
factors I
in O
different O
Th O
cell O
subsets O
. O

Following O
neutrophil O
stimulation O
with O
proinflammatory O
agonists O
( O
such O
as O
lipopolysaccharide O
[ O
LPS O
] O
, O
tumor B
necrosis I
factor I
- I
alpha I
[ O
TNF B
- I
alpha I
] O
, O
and O
fMet O
- O
Leu O
- O
Phe O
) O
that O
induce O
the O
production O
of O
cytokines B
and O
chemokines B
in O
these O
cells O
, O
NF B
- I
kappaB I
/ I
Rel I
proteins I
translocated O
to O
nuclear O
fractions O
, O
resulting O
in O
a O
transient O
induction O
of O
NF B
- I
kappaB I
DNA O
binding O
activity O
, O
as O
determined O
in O
gel O
mobility O
shift O
assays O
. O

Stimulation O
of O
CD2 B
or O
TCR B
/ I
CD3 I
induced O
activation O
of O
the O
nuclear B
factor I
of I
activated I
T I
cells I
( O
NFAT B
) O
, O
the O
binding B
site I
of O
which O
is O
included O
in O
the O
IL B
- I
2 I
gene I
promoter I
. O

This O
transcription B
factor I
is O
activated O
via O
the O
selective O
phosphorylation O
, O
ubiquination O
and O
degradation O
of O
its O
inhibitor B
protein I
I I
- I
kB I
thereby O
allowing O
translocation O
of O
NF B
- I
kappa I
B I
into O
the O
nucleus O
where O
it O
upregulates O
the O
transcription O
of O
a O
variety O
of O
adhesion B
molecules I
( O
e O
. O
g O
. O
ICAM B
- I
1 I
, O
VCAM B
- I
1 I
) O
, O
cytokines B
( O
TNF B
, O
IL B
- I
1 I
, O
IL B
- I
6 I
) O
and O
enzymes B
( O
iNOS B
) O
. O

Understanding O
the O
cis B
- I
and I
transacting I
factors I
that O
regulate O
the O
tissue O
- O
specific O
expression O
of O
PECAM B
- I
1 I
should O
increase O
our O
understanding O
of O
the O
mechanisms O
by O
which O
vascular O
- O
specific O
gene O
expression O
is O
achieved O
. O

Interaction O
of O
transcription B
factors I
RFX1 B
and O
MIBP1 B
with O
the O
gamma B
motif I
of O
the O
negative B
regulatory I
element I
of O
the O
hepatitis B
B I
virus I
core I
promoter I
. O

A O
T B
cell I
- I
specific I
enhancer I
in O
the O
interleukin B
- I
3 I
locus I
is O
activated O
cooperatively O
by O
Oct B
and I
NFAT I
elements I
within O
a O
DNase B
I I
- I
hypersensitive I
site I
. O

A O
T B
cell I
- I
specific I
enhancer I
in O
the O
interleukin B
- I
3 I
locus I
is O
activated O
cooperatively O
by O
Oct B
and I
NFAT I
elements I
within O
a O
DNase B
I I
- I
hypersensitive I
site I
. O

We O
suggest O
that O
the O
T O
cell O
- O
specific O
expression O
of O
the O
IL B
- I
3 I
gene I
is O
partly O
controlled O
through O
the O
enhancer O
by O
cooperation O
between O
Oct B
and I
NFAT I
family I
proteins I
. O

Activation O
of O
Ras O
and O
mitogen B
- I
activated I
protein I
kinase I
pathway O
by O
terminal B
complement I
complexes I
is O
G B
protein I
dependent O
. O

Contrary O
to O
the O
results O
in O
Jurkat O
cells O
, O
PDTC O
did O
not O
inhibit O
tumor B
necrosis I
factor I
- I
alpha I
- O
induced O
NF B
kappaB I
activation O
in O
astrocytes O
; O
instead O
PDTC O
itself O
induces O
NF B
kappaB I
activation O
in O
astrocytes O
, O
and O
this O
may O
be O
related O
to O
scavenging O
of O
endogenously O
produced O
NO O
by O
the O
PDTC O
iron O
complex O
. O

In O
astrocytes O
PDTC O
also O
dramatically O
induces O
the O
NF B
kappaB I
- I
dependent I
enzyme I
, O
iNOS B
, O
supporting O
the O
physiologic O
relevance O
of O
endogenous O
NO O
regulation O
of O
NF B
kappaB I
. O

Moreover O
, O
EGF O
treatment O
induced O
Stat3 B
phosphorylation O
in O
cells O
transfected O
with O
the O
intact O
chimeric B
EGF I
- I
gp130 I
receptor I
along O
with O
induction O
of O
DNA O
- O
mobility O
shift O
of O
a O
classical B
interferon I
- I
gamma I
- I
activated I
site I
. O

The O
transcriptional B
regulatory I
elements I
of O
many O
inducible B
T I
- I
cell I
genes I
contain O
adjacent O
or O
overlapping B
binding I
sites I
for O
the O
Ets B
and I
NF I
- I
kappaB I
/ I
NFAT I
families I
of O
transcription B
factors I
. O

The O
DNA B
- I
binding I
domain I
( O
amino B
acids I
421 I
- I
486 I
) O
is O
completely O
conserved O
among O
human B
, I
squirrel I
monkey I
, I
owl I
monkey I
, I
and I
cotton I
- I
top I
tamarin I
receptors I
. O

Shared O
gamma B
( I
c I
) I
subunit I
within O
the O
human B
interleukin I
- I
7 I
receptor I
complex I
. O

The O
gamma B
( I
c I
) I
subunit I
can O
be O
employed O
in O
receptor B
complexes I
for O
IL B
- I
2 I
, I
- I
4 I
, I
- I
7 I
, I
- I
9 I
, I
and I
- I
15 I
, O
and O
the O
multiple O
signaling O
defects O
that O
would O
result O
from O
a O
defective O
gamma B
( I
c I
) I
chain I
in O
these O
receptors O
are O
proposed O
to O
cause O
the O
severe O
phenotype O
of O
X O
- O
SCID O
patients O
. O

The O
gamma B
( I
c I
) I
subunit I
can O
be O
employed O
in O
receptor B
complexes I
for O
IL B
- I
2 I
, I
- I
4 I
, I
- I
7 I
, I
- I
9 I
, I
and I
- I
15 I
, O
and O
the O
multiple O
signaling O
defects O
that O
would O
result O
from O
a O
defective O
gamma B
( I
c I
) I
chain I
in O
these O
receptors O
are O
proposed O
to O
cause O
the O
severe O
phenotype O
of O
X O
- O
SCID O
patients O
. O

Thymocytes O
expressed O
four O
- O
to O
10 O
- O
fold O
greater O
amounts O
of O
the O
3 B
. I
5 I
kb I
transcript I
than O
other O
tissues O
. O

In O
the O
rare O
hybrids O
that O
continue O
to O
express O
Ig O
, O
all O
other O
tested O
B B
lymphocyte I
- I
specific I
genes I
also O
remain O
active O
. O

In O
mobility O
shift O
assays O
, O
a O
nuclear B
factor I
from O
THP O
- O
1 O
and O
U O
- O
937 O
cells O
was O
identified O
that O
binds O
to O
several O
AP B
- I
2 I
response I
elements I
within O
the O
B2 B
promoter I
, O
but O
does O
not O
react O
with O
AP B
- I
2 I
antibodies I
, O
and O
has O
a O
DNA B
sequence I
binding O
affinity O
profile O
that O
differs O
from O
AP B
- I
2 I
. O

These O
findings O
suggest O
that O
a O
novel O
AP B
- I
2 I
- I
like I
transcription I
factor I
is O
responsible O
for O
V B
- I
ATPase I
B I
subunit I
amplification O
during O
monocyte O
differentiation O
. O

The O
upstream O
regions O
UAS3 B
( O
- B
1168 I
to I
- I
440 I
) O
and O
UAS2 B
( O
- B
352 I
to I
- I
264 I
) O
both O
functioned O
in O
a O
cell O
lineage O
- O
independent O
manner O
and O
were O
together O
responsible O
for O
the O
bulk O
of O
Wp O
activity O
in O
non O
- O
B O
cells O
; O
mutational O
analysis O
indicated O
the O
importance O
of O
a O
YY1 B
binding I
site I
in O
UAS2 B
in O
that O
context O
. O

The O
upstream O
regions O
UAS3 B
( O
- B
1168 I
to I
- I
440 I
) O
and O
UAS2 B
( O
- B
352 I
to I
- I
264 I
) O
both O
functioned O
in O
a O
cell O
lineage O
- O
independent O
manner O
and O
were O
together O
responsible O
for O
the O
bulk O
of O
Wp O
activity O
in O
non O
- O
B O
cells O
; O
mutational O
analysis O
indicated O
the O
importance O
of O
a O
YY1 B
binding I
site I
in O
UAS2 B
in O
that O
context O
. O

By O
contrast O
, O
UAS1 B
( O
- B
140 I
to I
- I
87 I
) O
was O
B O
cell O
specific O
and O
was O
the O
key O
determinant O
of O
the O
promoter O
' O
s O
increased O
activity O
in O
B O
cell O
lines O
. O

Blood O
monocytes O
spontaneously O
activate O
endothelial O
cells O
in O
culture O
, O
leading O
to O
adhesion O
of O
monocytic O
cells O
onto O
the O
endothelial O
surface O
and O
overproduction O
of O
endothelial O
proteins O
such O
as O
von B
Willebrand I
factor I
( O
vWf B
) O
and O
plasminogen B
activator I
inhibitor I
type I
1 I
( O
PAI B
- I
1 I
) O
. O

These O
results O
indicate O
that O
dexamethasone O
is O
able O
to O
abrogate O
the O
transcriptional O
activity O
of O
the O
human B
granzyme I
B I
gene I
promoter I
by O
inhibiting O
the O
binding O
of O
nuclear B
factors I
at O
the O
AP B
- I
1 I
and I
Ikaros I
sites I
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B B
cell I
adaptor I
containing I
SH2 I
domain I
) O
, O
that O
contains O
N B
- I
terminal I
acidic I
domains I
with O
SH2 B
domain I
- I
binding I
phosphotyrosine I
- I
based I
motifs I
, O
a O
proline B
- I
rich I
domain I
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

The O
gene O
encodes O
an O
85 B
- I
kDa I
protein I
, O
designated O
BASH B
( O
B B
cell I
adaptor I
containing I
SH2 I
domain I
) O
, O
that O
contains O
N B
- I
terminal I
acidic I
domains I
with O
SH2 B
domain I
- I
binding I
phosphotyrosine I
- I
based I
motifs I
, O
a O
proline B
- I
rich I
domain I
, O
and O
a O
C B
- I
terminal I
SH2 I
domain I
. O

The O
action O
of O
adenoviral B
E1A I
oncoprotein I
on O
host B
immune I
- I
response I
genes I
has O
been O
attributed O
to O
interaction O
with O
p300 B
/ I
CBP I
- I
type I
transcriptional I
coactivators I
in O
competition O
with O
endogenous B
transcription I
factors I
such O
as O
signal B
transducer I
and I
activator I
of I
transcription I
( I
STAT I
) I
proteins I
. O

We O
show O
here O
that O
IFN B
- I
alpha I
/ I
beta I
act O
directly O
on O
human O
T O
cells O
to O
drive O
Th1 O
development O
, O
bypassing O
the O
need O
for O
IL B
- I
12 I
- O
induced O
signaling O
, O
whereas O
IFN B
- I
alpha I
can O
not O
substitute O
IL B
- I
12 I
for O
mouse O
Th1 O
development O
. O

Unlike O
IL B
- I
12 I
, O
which O
acts O
only O
on O
Th1 O
cells O
, O
IFN B
- I
alpha I
/ I
beta I
can O
activate O
Stat4 B
not O
only O
in O
human O
Th1 O
, O
but O
also O
in O
Th2 O
cells O
. O

LOX B
- I
1 I
is O
an O
endothelial B
receptor I
for O
oxidized B
low I
- I
density I
lipoprotein I
that O
plays O
essential O
roles O
in O
atherogenesis O
. O

In O
the O
present O
study O
, O
we O
cloned O
and O
characterized O
the O
human B
LOX I
- I
1 I
gene I
( O
HGMW B
- I
approved I
symbol I
OLR1 I
) O
. O

In O
the O
present O
study O
, O
we O
cloned O
and O
characterized O
the O
human B
LOX I
- I
1 I
gene I
( O
HGMW B
- I
approved I
symbol I
OLR1 I
) O
. O

These O
results O
demonstrate O
that O
the O
human B
LOX I
- I
1 I
gene I
is O
a O
new O
member O
of O
the O
natural B
killer I
gene I
complex I
with O
a O
unique O
expression O
profile O
. O

An O
81 O
% O
increment O
in O
promoter O
activity O
was O
obtained O
when O
a O
mutation O
was O
introduced O
in O
the O
GATA B
- I
3 I
binding I
site I
of O
the O
bp B
- I
267 I
to I
+ I
12 I
construct I
, O
which O
is O
comparable O
to O
that O
of O
the O
bp B
- I
245 I
to I
+ I
12 I
construct I
. O

Neither O
the O
E12 B
nor O
the O
E47 B
product O
of O
the O
E2A B
gene I
nor O
the O
wild B
- I
type I
HLF I
protein I
was O
able O
to O
protect O
the O
cells O
from O
apoptosis O
induced O
by O
IL B
- I
3 I
deprivation O
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

These O
results O
suggest O
that O
1 O
) O
lipid O
A O
myristoyl O
fatty O
acid O
, O
although O
it O
is O
important O
for O
the O
induction O
of O
inflammatory B
cytokine I
production O
by O
human O
monocytes O
, O
is O
not O
necessary O
for O
the O
induction O
of O
Mn B
SOD I
, O
2 O
) O
endotoxin B
- O
mediated O
induction O
of O
Mn B
SOD I
and O
inflammatory O
cytokines B
are O
regulated O
, O
at O
least O
in O
part O
, O
through O
different O
signal O
transduction O
pathways O
, O
and O
3 O
) O
failure O
of O
the O
mutant B
endotoxin I
to O
induce O
tumor B
necrosis I
factor I
- I
alpha I
production O
is O
, O
at O
least O
in O
part O
, O
due O
to O
its O
inability O
to O
activate O
mitogen B
- I
activated I
protein I
kinase I
. O

Replication O
of O
human O
immunodeficiency O
virus O
type O
- O
1 O
( O
HIV O
- O
1 O
) O
is O
highly O
dependent O
on O
the O
state O
of O
activation O
of O
the O
infected O
cells O
and O
is O
modulated O
by O
interactions O
between O
viral B
and I
host I
cellular I
factors I
. O

Unexpectedly O
, O
we O
found O
that O
conventional O
procedures O
employed O
to O
prepare O
cellular O
extracts O
cause O
the O
release O
of O
proteolytic O
activities O
that O
are O
normally O
stored O
in O
intracellular O
granules O
, O
resulting O
in O
the O
degradation O
of O
various O
NF B
- I
kappaB I
/ I
Rel I
and O
STAT B
proteins I
. O

PDBu O
+ O
iono O
induced O
equally O
high O
IL B
- I
2 I
levels O
in O
both O
groups O
and O
, O
when O
stimulated O
with O
plate O
- O
bound O
anti B
- I
CD3 I
monoclonal I
antibody I
( O
mAb B
) O
, O
the O
IL B
- I
2 I
secretion O
by O
neonatal O
cells O
was O
undetectable O
and O
adult O
cells O
produced O
low O
amounts O
of O
IL B
- I
2 I
( O
mean O
331 O
+ O
/ O
- O
86 O
pg O
/ O
ml O
) O
. O

Our O
results O
suggest O
that O
reduced O
IL B
- I
2 I
production O
by O
neonatal O
T O
cells O
is O
specific O
for O
anti B
- I
CD3 I
and O
anti B
- I
CD3 I
+ O
anti B
- I
CD28 I
- O
mediated O
stimulation O
and O
that O
these O
activators O
can O
not O
effectively O
activate O
the O
ROI O
- B
NF I
- I
kappa I
B I
signalling O
pathway O
in O
neonatal O
T O
cells O
. O

The O
eosinophilic O
characteristics O
of O
YJ O
cells O
were O
confirmed O
by O
histochemical O
staining O
with O
Fast O
- O
Green O
/ O
Neutral O
- O
Red O
and O
by O
the O
expression O
of O
mRNAs B
for O
eosinophil B
- I
associated I
granule I
proteins I
, O
eosinophil B
cationic I
protein I
( O
ECP B
) O
, O
eosinophil B
- I
derived I
neurotoxin I
( O
EDN B
) O
, O
eosinophil B
peroxidase I
( O
EPO B
) O
, O
and O
major B
basic I
protein I
( O
MBP B
) O
, O
and O
for O
the O
Charcot B
- I
Leyden I
crystal I
( I
CLC I
) I
protein I
. O

The O
differential O
expression O
of O
the O
genes O
in O
the O
zinc B
finger I
and I
POU I
families I
will O
lead O
to O
a O
better O
understanding O
of O
the O
cascade O
of O
gene O
expression O
which O
occurs O
following O
ATRA O
- O
induced O
differentiation O
. O

The O
cytokine B
- O
dependent O
upregulation O
of O
the O
murine B
macrophage I
12 I
- I
lipoxygenase I
and O
its O
induction O
during O
experimental O
anemia O
suggests O
its O
close O
relatedness O
with O
the O
human B
reticulocyte I
- I
type I
15 I
- I
lipoxygenase I
despite O
their O
differences O
in O
the O
positional O
specificity O
of O
arachidonic O
acid O
oxygenation O
. O

Differential O
responsiveness O
of O
the O
IL B
- I
5 I
and I
IL I
- I
4 I
genes I
to O
transcription B
factor I
GATA I
- I
3 I
. O

The O
Duffy B
protein I
is O
a O
receptor O
for O
the O
Plasmodium B
vivax I
erythrocyte I
- I
binding I
protein I
and O
is O
also O
a O
receptor O
for O
various O
chemokines B
( O
thus O
renamed O
Duffy B
Antigen I
Receptor I
for I
Chemokines I
[ O
DARC B
] O
) O
. O

The O
transcription B
factors I
active O
at O
the O
IL B
- I
2 I
promoter I
were O
differentially O
influenced O
: O
upon O
down O
- O
modulation O
of O
okadaic B
acid I
- I
sensitive I
phosphatases I
, O
transactivation O
by O
octamer O
, O
NF B
- I
kappa I
B I
, O
and O
NF B
of I
activated I
T I
cells I
proteins I
was O
abrogated O
, O
while O
transactivation O
by O
AP B
- I
1 I
proteins I
was I
even I
enhanced I
. I

IL B
- I
12 I
is O
a O
75 B
- I
kDa I
heterodimeric I
cytokine I
composed O
of O
two O
covalently O
linked O
p35 B
and I
p40 I
chains I
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

Analyzed O
DNA B
sequences I
included O
delta B
and I
beta I
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
500 I
to I
+ I
50bp I
( O
promoter B
regions I
) O
, O
truncated O
delta O
and O
beta B
5 I
' I
flanking I
regions I
extending O
from O
approximately O
- B
250 I
to I
+ I
50 I
bp I
, O
and O
chimeric B
promoter I
constructions I
, O
which O
consisted O
of O
a O
distal O
delta B
or I
beta I
fragment I
fused O
to O
a O
proximal B
beta I
or I
delta I
sequence I
. O

Fusion O
of O
the O
upstream B
portion I
of O
the O
delta B
promoter I
to O
the O
truncated O
beta B
globin I
promoter I
yielded O
a O
modest O
increase O
in O
promoter O
strength O
relative O
to O
the O
truncated B
beta I
gene I
promoter I
, O
indicating O
the O
presence O
of O
a O
positive B
transcriptional I
element I
( O
s O
) O
in O
the O
upstream B
delta I
globin I
regulatory I
region I
. O

The O
transition O
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
from O
latency O
into O
the O
lytic O
cycle O
is O
associated O
with O
the O
expression O
of O
two O
immediate B
- I
early I
viral I
genes I
, O
BZLF1 B
and O
BRLF1 B
. O

Previously O
, O
we O
demonstrated O
that O
granulocyte B
colony I
- I
stimulating I
factor I
( I
G I
- I
CSF I
) I
receptor I
mRNA I
was O
undetectable O
and O
granulocyte O
maturation O
blocked O
in O
CCAAT B
enhancer I
binding I
protein I
alpha I
( O
C B
/ I
EBPalpha I
) O
- O
deficient O
mice O
. O

The O
role O
of O
platelets O
for O
monocyte B
chemotactic I
protein I
- I
1 I
( O
MCP B
- I
1 I
) O
secretion O
and O
surface O
expression O
of O
intercellular O
adhesion O
molecule O
- O
1 O
( O
ICAM B
- I
1 I
) O
on O
endothelial O
cells O
has O
been O
assessed O
. O

Here O
we O
investigated O
the O
impact O
of O
retinoid B
X I
receptor I
( O
RXR B
) O
, O
retinoic B
acid I
receptor I
( O
RAR B
) O
, O
and O
of O
the O
c B
- I
erbA I
/ I
thyroid I
hormone I
( I
T3 I
) I
receptor I
( O
c B
- I
erbA I
/ I
TR I
) O
on O
growth O
and O
differentiation O
of O
erythroid O
cells O
using O
an O
in O
vitro O
culture O
system O
of O
stem O
cell O
factor O
- O
dependent O
erythroid O
progenitors O
. O

RXR B
, O
RAR B
, O
and O
c B
- I
erbA I
/ I
TR I
- O
specific O
ligands O
were O
found O
to O
induce O
erythroid B
- I
specific I
gene I
expression O
and O
to O
accelerate O
erythroid O
differentiation O
in O
culture O
, O
with O
T3 O
being O
most O
effective O
. O

Thus O
, O
c B
- I
erbA I
/ I
TR I
appears O
to O
act O
as O
a O
binary O
switch O
affecting O
erythroid O
cell O
fate O
: O
unliganded O
c B
- I
erbA I
/ I
TR I
supports O
growth O
while O
ligand O
- O
activated O
c B
- I
erbA I
/ I
TR I
induces O
differentiation O
. O

Thus O
, O
c B
- I
erbA I
/ I
TR I
appears O
to O
act O
as O
a O
binary O
switch O
affecting O
erythroid O
cell O
fate O
: O
unliganded O
c B
- I
erbA I
/ I
TR I
supports O
growth O
while O
ligand O
- O
activated O
c B
- I
erbA I
/ I
TR I
induces O
differentiation O
. O

Thus O
, O
c B
- I
erbA I
/ I
TR I
appears O
to O
act O
as O
a O
binary O
switch O
affecting O
erythroid O
cell O
fate O
: O
unliganded O
c B
- I
erbA I
/ I
TR I
supports O
growth O
while O
ligand O
- O
activated O
c B
- I
erbA I
/ I
TR I
induces O
differentiation O
. O

In O
marked O
contrast O
, O
expression O
of O
the O
dominant B
interfering I
deltaDNA I
- I
binding I
domain I
RXR B
, O
containing O
a O
deletion O
of O
the O
entire B
DNA I
- I
binding I
domain I
, O
was O
incompatible O
with O
erythroid O
cell O
growth O
in O
vitro O
, O
suggesting O
a O
pivotal O
role O
of O
RXR B
for O
erythroid O
cell O
development O
. O

T O
lymphocytes O
from O
6 O
of O
the O
14 O
patients O
also O
exhibited O
an O
increased O
expression O
of O
the O
dual O
specificity B
phosphatase I
, O
map B
kinase I
phosphatase I
- I
1 I
( O
MKP B
- I
1 I
) O
. O

The O
effect O
of O
Rho B
on O
AP B
- I
1 I
is O
independent O
of O
the O
mitogen B
- I
activated I
protein I
kinase I
pathway O
, O
as O
a O
dominant B
- I
negative I
MEK I
and O
a O
MEK B
inhibitor O
( O
PD98059 O
) O
did O
not O
affect O
Rho B
- O
induced O
AP B
- I
1 I
activity O
. O

Data O
obtained O
by O
electrophoretic O
mobility O
shift O
assay O
suggested O
that O
the O
activated B
Stat I
- I
3 I
protein I
associates O
with O
the O
human B
serum I
- I
inducible I
element I
( I
hSIE I
) I
DNA I
- I
probe I
derived O
from O
the O
interferon B
- I
gamma I
activated I
site I
( O
GAS B
) O
in O
the O
c B
- I
fos I
promoter I
, O
a O
common O
DNA O
sequence O
for O
Stat B
protein I
binding O
. O

Data O
obtained O
by O
electrophoretic O
mobility O
shift O
assay O
suggested O
that O
the O
activated B
Stat I
- I
3 I
protein I
associates O
with O
the O
human B
serum I
- I
inducible I
element I
( I
hSIE I
) I
DNA I
- I
probe I
derived O
from O
the O
interferon B
- I
gamma I
activated I
site I
( O
GAS B
) O
in O
the O
c B
- I
fos I
promoter I
, O
a O
common O
DNA O
sequence O
for O
Stat B
protein I
binding O
. O

Porcine B
MHC I
class I
II I
antigens I
are O
potent O
stimulators O
of O
direct O
T O
- O
cell O
recognition O
by O
human O
CD4 O
+ O
T O
cells O
and O
are O
, O
therefore O
, O
likely O
to O
play O
an O
important O
role O
in O
the O
rejection O
responses O
to O
transgenic O
pig O
donors O
in O
clinical O
xenotransplantation O
. O

MyD88 B
, O
originally O
isolated O
as O
a O
myeloid O
differentiation O
primary B
response I
gene I
, O
is O
shown O
to O
act O
as O
an O
adaptor O
in O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
signaling O
by O
interacting O
with O
both O
the O
IL B
- I
1 I
receptor I
complex I
and O
IL B
- I
1 I
receptor I
- I
associated I
kinase I
( O
IRAK B
) O
. O

In O
addition O
, O
transcriptional O
activity O
of O
IL B
- I
2 I
and O
metallothionein B
enhancer I
and I
promoter I
regions I
and O
transcription B
factors I
AP B
- I
1 I
, O
NF B
- I
kappaB I
, O
and O
NF B
- I
AT I
were O
analyzed O
by O
chloramphenicol B
acetyltransferase I
( O
CAT B
) O
and O
electrophoretic O
mobility O
shift O
assays O
, O
respectively O
. O

Because O
the O
GATA B
- I
1 I
gene I
is O
located O
on O
the O
X B
chromosome I
, O
which O
is O
randomly O
inactivated O
in O
every O
cell O
, O
heterozygous O
females O
can O
bear O
either O
an O
active O
wild O
- O
type O
or O
mutant O
( O
referred O
to O
as O
GATA B
- I
1 I
. I
05 I
) O
GATA B
- I
1 I
allele O
, O
consequently O
leading O
to O
variable O
anemic O
severity O
. O

Other O
bacterial O
toxins O
, O
tumor B
necrosis I
factor I
- I
alpha I
( O
TNF B
) O
, O
interleukin B
- I
1 I
( O
IL B
- I
1 I
) O
, O
T B
cell I
mitogens I
, O
UV O
light O
, O
gamma O
rays O
and O
oxidative O
stress O
were O
reported O
to O
induce O
NF B
- I
kappa I
B I
. O

We O
localized O
the O
LAM O
- O
, O
lipopolysaccharide O
( O
LPS O
) O
- O
, O
and O
TNF B
- I
alpha I
- B
inducible I
promoter I
activity O
to O
a O
- O
131 O
/ O
+ O
15 O
( O
positions O
- O
131 O
to O
+ O
15 O
) O
DNA O
fragment O
of O
the O
IL B
- I
1 I
beta I
gene I
by O
deletion O
analysis O
and O
chloramphenicol B
acetyltransferase I
assay O
. O

Cell O
- O
type O
- O
specific O
transactivation O
of O
the O
parathyroid B
hormone I
- I
related I
protein I
gene I
promoter I
by O
the O
human B
T I
- I
cell I
leukemia I
virus I
type I
I I
( I
HTLV I
- I
I I
) I
tax I
and O
HTLV B
- I
II I
tax I
proteins I
. O

A O
carboxy B
terminal I
Tax I
deletion I
mutant I
was O
deficient O
in O
transactivation O
of O
both O
the O
PTHrP B
and I
IL2R I
alpha I
promoters I
but O
not O
the O
HTLV B
- I
I I
long I
terminal I
repeat I
( O
LTR B
) O
. O

A O
carboxy B
terminal I
Tax I
deletion I
mutant I
was O
deficient O
in O
transactivation O
of O
both O
the O
PTHrP B
and I
IL2R I
alpha I
promoters I
but O
not O
the O
HTLV B
- I
I I
long I
terminal I
repeat I
( O
LTR B
) O
. O

Activation O
of O
primary O
human O
T O
- O
lymphocytes O
through O
CD2 B
plus I
CD28 I
adhesion I
molecules I
induces O
long O
- O
term O
nuclear O
expression O
of O
NF B
- I
kappa I
B I
. O

The O
eukaryotic O
transcription B
factor I
nuclear B
factor I
- I
kappa I
B I
( O
NF B
- I
kappa I
B I
) O
participates O
in O
many O
parts O
of O
the O
genetic O
program O
mediating O
T O
lymphocyte O
activation O
and O
growth O
. O

Transfection O
studies O
indicate O
that O
the O
I B
kappa I
B I
alpha I
gene I
is O
specifically O
induced O
by O
the O
65 B
- I
kilodalton I
transactivating I
subunit I
of O
NF B
- I
kappa I
B I
. O

Transfection O
studies O
indicate O
that O
the O
I B
kappa I
B I
alpha I
gene I
is O
specifically O
induced O
by O
the O
65 B
- I
kilodalton I
transactivating I
subunit I
of O
NF B
- I
kappa I
B I
. O

Dimerization O
of O
NF B
- I
KB2 I
with O
RelA B
( I
p65 I
) I
regulates O
DNA O
binding O
, O
transcriptional O
activation O
, O
and O
inhibition O
by O
an O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

Transcriptional O
activation O
of O
the O
HIV O
enhancer O
was O
also O
subject O
to O
regulation O
by O
recently O
cloned O
I B
kappa I
B I
- I
alpha I
( O
MAD B
- I
3 I
) O
. O

The O
c B
- I
rel I
protooncogene I
product I
represses O
NF B
- I
kappa I
B I
p65 B
- O
mediated O
transcriptional O
activation O
of O
the O
long O
terminal O
repeat O
of O
type O
1 O
human O
immunodeficiency O
virus O
. O

This O
intracellular O
signaling O
complex O
potently O
stimulates O
kappa O
B O
- O
directed O
transcription O
from O
either O
the O
HIV B
- I
1 I
LTR I
or O
the O
IL B
- I
2R I
alpha I
promoter I
via O
the O
strong O
transactivation O
domain O
present O
in O
p65 B
. O

Serum B
response I
factor I
( O
SRF B
) O
binds O
to O
a O
site O
adjacent O
to O
the O
NF B
- I
kappa I
B I
site I
in O
the O
IL B
- I
2R I
enhancer I
, O
and O
both O
sites O
together O
have O
strong O
transcriptional O
activity O
specifically O
in O
T O
cells O
. O

Mutual O
regulation O
of O
the O
transcriptional B
activator I
NF B
- I
kappa I
B I
and O
its O
inhibitor O
, O
I B
kappa I
B I
- I
alpha I
. O

In O
previous O
transfection O
analyses O
using O
the O
chloramphenicol B
acetyltransferase I
reporter B
gene I
system O
, O
we O
determined O
that O
linker O
substitution O
( O
LS O
) O
mutations O
between O
- B
201 I
and I
- I
130 I
( O
relative O
to O
the O
transcription O
start O
site O
) O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
long B
terminal I
repeat I
( O
LTR B
) O
caused O
moderate O
decreases O
in O
LTR B
transcriptional O
activity O
in O
a O
T O
- O
cell O
line O
( O
S O
. O
L O
. O
Zeichner O
, O
J O
. O
Y O
. O
H O
. O
Kim O
, O
and O
J O
. O
C O
. O
Alwine O
, O
J O
. O
Virol O
. O
65 O
: O
2436 O
- O
2444 O
, O
1991 O
) O
. O

Comparison O
of O
group O
1 O
human B
and I
mouse I
genomic I
sequences I
shows O
high O
conservation O
in O
the O
5 B
' I
flank I
and O
exons B
. O

Thus O
, O
the O
GATA B
- I
2 I
transcription I
factor I
appears O
to O
play O
a O
role O
in O
regulating O
the O
self O
- O
renewal O
capacity O
of O
early O
erythroid O
progenitor O
cells O
. O

Surprisingly O
, O
this O
was O
the O
case O
even O
when O
an O
antagonistic B
anti I
- I
TR55 I
antibody I
was O
used O
. O

Recent O
isolation O
of O
the O
CD11b B
promoter I
shows O
that O
92 O
base O
pairs O
( O
bp O
) O
of O
5 B
' I
- I
flanking I
DNA I
are O
sufficient O
to O
direct O
myeloid O
- O
specific O
expression O
of O
a O
reporter B
gene I
. O

R7 O
- O
57 O
reporter O
cells O
, O
on O
the O
other O
hand O
, O
signaled O
induced O
activity O
of O
the O
lytic B
origin I
of I
EBV I
replication I
( O
ori B
Lyt I
) O
. O

Costimulation O
of O
cAMP O
and O
protein B
kinase I
C I
pathways O
inhibits O
the O
CD3 B
- O
dependent O
T O
cell O
activation O
and O
leads O
to O
a O
persistent O
expression O
of O
the O
AP B
- I
1 I
transcription I
factor I
. O

We O
combined O
two O
techniques O
to O
identify O
the O
productive O
replicative O
form O
of O
Epstein B
- I
Barr I
viral I
DNA I
in O
the O
lytic O
cycle O
- O
induced O
cells O
. O

Increased O
c B
- I
jun I
, O
jun B
- I
B I
, O
and O
jun B
- I
D I
expression O
above O
basal O
levels O
and O
increased O
transcriptional O
activity O
of O
AP B
- I
1 I
/ I
TPA I
responsive I
elements I
fused O
to O
chloramphenicol B
acetyl I
- I
transferase I
vectors I
were O
observed O
in O
T O
cells O
treated O
with O
TPA O
alone O
or O
in O
combination O
with O
dexamethasone O
. O

Despite O
this O
lower O
affinity O
, O
a O
trimer O
of O
the O
BAT B
box I
sequence I
was O
as O
efficiently O
transactivated O
by O
an O
Oct B
- I
2 I
expression I
vector I
as O
was O
a O
trimer O
of O
the O
octamer B
sequence I
in O
HeLa O
cells O
. O

HL O
- O
60 O
cells O
constitutively O
expressing O
an O
Egr B
- I
1 I
transgene I
( O
HL B
- I
60Egr I
- I
1 I
) O
could O
be O
induced O
for O
macrophage O
, O
but O
not O
granulocyte O
, O
differentiation O
. O

Thus O
, O
these O
experiments O
demonstrate O
that O
EBNA2 B
interacts O
with O
an O
EBNA2 B
responsive I
cis I
- I
element I
of O
the O
TP1 B
promoter I

Cotransfection O
of O
an O
hGATA B
- I
3 I
expression I
plasmid I
with O
a O
reporter B
plasmid I
whose O
transcription O
is O
directed O
by O
the O
HIV B
- I
1 I
LTR I
resulted O
in O
6 O
- O
to O
10 O
- O
fold O
stimulation O
of O
LTR B
- O
mediated O
transcription O
, O
whereas O
site O
specific O
mutation O
of O
these O
GATA B
sites I
resulted O
in O
virtual O
abrogation O
of O
the O
activation O
by O
hGATA B
- I
3 I
. O

Cloning O
and O
functional O
characterization O
of O
early B
B I
- I
cell I
factor I
, O
a O
regulator O
of O
lymphocyte O
- O
specific O
gene O
expression O
. O

Early B
B I
- I
cell I
factor I
( O
EBF B
) O
was O
identified O
previously O
as O
a O
tissue O
- O
specific O
and O
differentiation O
stage O
- O
specific O
DNA B
- I
binding I
protein I
that O
participates O
in O
the O
regulation O
of O
the O
pre B
- I
B I
and I
B I
lymphocyte I
- I
specific I
mb I
- I
1 I
gene I
. O

Deletions O
delineated O
a O
carboxy B
- I
terminal I
dimerization I
region I
containing O
two O
repeats O
of O
15 O
amino O
acids O
that O
show O
similarity O
with O
the O
dimerization B
domains I
of O
basic B
- I
helix I
- I
loop I
- I
helix I
proteins I
. O

This O
high B
- I
affinity I
site I
has O
been O
conserved O
in O
the O
promoters B
of O
both O
human B
and I
mouse I
CD19 I
genes I
and O
was O
furthermore O
shown O
to O
confer O
B O
- O
cell O
specificity O
to O
a O
beta O
- O
globin O
reporter O
gene O
in O
transient O
transfection O
experiments O
. O

Radiolabeled B
hormone I
/ I
receptor I
complexes I
of O
nuclei O
isolated O
from O
cells O
exposed O
for O
3 O
h O
to O
radiolabeled O
hormone O
- O
- O
in O
contrast O
to O
identical O
experiments O
with O
intact O
cells O
- O
- O
did O
not O
disappear O
from O
the O
nuclear O
compartment O
upon O
incubation O
of O
nuclei O
with O
identical O
concentrations O
of O
the O
unlabeled O
compound O
. O

Okadaic O
acid O
is O
a O
potent O
inducer O
of O
AP B
- I
1 I
, O
NF B
- I
kappa I
B I
, O
and O
tumor B
necrosis I
factor I
- I
alpha I
in O
human O
B O
lymphocytes O
. O

A O
T B
cell I
- I
specific I
protein I
Neg B
- I
1 I
and O
a O
ubiquitous B
protein I
Neg B
- I
2 I
binding O
to O
NRE B
- I
I I
and O
NRE B
- I
II I
, O
respectively O
, O
were O
identified O
. O

Pit B
- I
1 I
is O
a O
pituitary B
- I
specific I
transcription I
factor I
that O
binds O
to O
and O
transactivates O
promoters B
of O
growth B
hormone I
and I
prolactin I
genes I
. O

Pit B
- I
1 I
is O
a O
pituitary B
- I
specific I
transcription I
factor I
that O
binds O
to O
and O
transactivates O
promoters B
of O
growth B
hormone I
and I
prolactin I
genes I
. O

In O
vivo O
footprint O
analysis O
of O
the O
HLA B
- I
DRA I
gene I
promoter I
: O
cell O
- O
specific O
interaction O
at O
the O
octamer B
site I
and O
up O
- O
regulation O
of O
X O
box O
binding O
by O
interferon B
gamma I
. O

In O
contrast O
, O
NF B
- I
kappa I
B I
p50 I
alone O
fails O
to O
stimulate O
kappa O
B O
- O
directed O
transcription O
, O
and O
based O
on O
prior O
in O
vitro O
studies O
, O
is O
not O
directly O
regulated O
by O
I B
kappa I
B I
. O

Together O
, O
these O
findings O
suggest O
that O
the O
nuclear O
localization O
signal O
and O
transactivation B
domain I
of O
NF B
- I
kappa I
B I
p65 I
constitute O
a O
bipartite O
system O
that O
is O
critically O
involved O
in O
the O
inhibitory O
function O
of O
I B
kappa I
B I
/ I
MAD I
- I
3 I
. O

This O
interaction O
is O
functional O
as O
it O
leads O
to O
retargeting O
of O
NF B
- I
kappa I
B I
p50 I
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

However O
, O
no O
loss O
of O
DNA O
binding O
activity O
is O
observed O
, O
presumably O
reflecting O
the O
unique O
C B
- I
terminal I
domain I
that O
is O
distinct O
from O
that O
present O
in O
NF B
- I
kappa I
B I
p65 I
. O

After O
the O
DNA B
fragment I
containing O
the O
CAG B
repeats I
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end B
- I
labelled I
reverse I
primer I
adjacent O
to O
3 B
' I
end I
of O
CAG B
repeats I
stops O
at O
the O
first O
T O
after O
CAG B
repeats I
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

Specific O
NF B
- I
kappa I
B I
subunits I
act O
in O
concert O
with O
Tat B
to O
stimulate O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
. O

NF B
- I
kappa I
B I
is O
a O
protein B
complex I
which O
functions O
in O
concert O
with O
the O
tat B
- I
I I
gene I
product I
to O
stimulate O
human O
immunodeficiency O
virus O
( O
HIV O
) O
transcription O
. O

Activation O
by O
the O
T B
- I
cell I
antigen I
receptor I
is O
minimal O
in O
Jurkat O
cells O
and O
is O
mediated O
by O
the O
kappa B
B I
sites I
. O

The O
promoter O
of O
the O
major B
histocompatibility I
class I
II I
gene I
DRA B
contains O
an O
octamer B
element I
( O
ATTTGCAT O
) O
that O
is O
required O
for O
efficient O
DRA B
expression O
in O
B O
cells O
. O

Recombinant B
OTF I
- I
2 I
protein I
produced O
by O
in O
vitro O
transcription O
/ O
translation O
could O
also O
enhance O
DRA B
gene I
transcription O
in O
vitro O
. O

The O
C B
- I
terminus I
has O
a O
putative O
protein B
kinase I
C I
phosphorylation I
site I
. O

A O
DNA B
probe I
that O
spanned O
a O
domain O
conserved O
among O
the O
proto B
- I
oncogene I
c I
- I
rel I
, O
the O
Drosophila B
morphogen I
dorsal I
, O
and O
the O
p50 B
DNA I
binding I
subunit I
of O
NF B
- I
kappa I
B I
was O
generated O
from O
Jurkat B
T I
cell I
complementary I
DNA I
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

This O
probe O
was O
used O
to O
identify O
a O
rel B
- I
related I
complementary I
DNA I
that O
hybridized O
to O
a O
2 B
. I
6 I
- I
kilobase I
messenger I
RNA I
present O
in O
human O
T O
and O
B O
lymphocytes O
. O

This O
protein B
- I
DNA I
complex I
comigrated O
with O
the O
complex O
obtained O
with O
the O
purified B
human I
p65 I
NF I
- I
kappa I
B I
subunit I
and O
binding O
was O
inhibited O
by O
I B
kappa I
B I
- I
alpha I
and O
- O
beta O
proteins O
. O

Regulation O
of O
M B
- I
CSF I
expression O
by O
M B
- I
CSF I
: O
role O
of O
protein B
kinase I
C I
and O
transcription B
factor I
NF I
kappa I
B I
. O

One O
gene O
of O
interest O
is O
the O
glycoprotein B
IIb I
( I
GPIIb I
) I
gene I
; O
GPIIb B
, O
the O
alpha B
subunit I
of O
the O
platelet B
cytoadhesin I
GPIIb I
- I
IIIa I
, O
is O
produced O
in O
megakaryocytes O
at O
an O
early O
stage O
of O
the O
differentiation O
, O
whereas O
the O
other O
subunit O
of O
this O
complex O
, O
GPIIIa B
, O
is O
expressed O
in O
other O
cells O
. O

The O
conversion O
of O
the O
TCEd B
to O
a O
' B
perfect I
' I
NF I
- I
kB I
binding I
site I
leads O
to O
a O
tighter O
binding O
of O
NF B
- I
kB I
to O
TCEd B
DNA I
and O
, O
as O
a O
functional O
consequence O
, O
to O
the O
activity O
of O
the O
' B
converted I
' I
TCEd I
motifs I
in O
HeLa O
cells O
. O

Finally O
, O
RNA O
from O
activated O
lymphocytes O
was O
amplified O
by O
polymerase O
chain O
reaction O
using O
oligonucleotide O
primers O
flanking O
the O
196 B
base I
pair I
long I
region I
encoding O
the O
DNA B
- I
binding I
domain I
of O
the O
human B
intestinal I
receptor I
. O

Previously O
, O
a O
nuclear B
factor I
, O
IRF B
- I
1 I
( O
interferon B
regulatory I
factor I
1 I
) O
, O
which O
binds O
to O
type B
I I
IFN I
and O
some O
IFN B
- I
inducible I
gene I
promoters I
, O
was O
identified O
and O
cloned O
. O

A O
dimerization B
cofactor I
of O
HNF B
- I
1 I
alpha I
( O
DCoH B
) O
was O
identified O
that O
displayed O
a O
restricted O
tissue O
distribution O
and O
did O
not O
bind O
to O
DNA O
, O
but O
, O
rather O
, O
selectively O
stabilized O
HNF B
- I
1 I
alpha I
dimers I
. O

Transforming B
growth I
factor I
- I
beta I
suppresses O
human B
B I
lymphocyte I
Ig I
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane B
form I
to O
the O
secreted B
form I
of O
Ig B
mRNA I
. O

There O
is O
a O
suitably O
located O
TATA B
box I
, O
but O
potential O
sites O
for O
CCAAT B
- I
box I
binding I
factors I
are O
far O
upstream O
, O
embedded O
in O
a O
42 B
- I
nucleotide I
repeat I
element I
. O

There O
is O
a O
suitably O
located O
TATA B
box I
, O
but O
potential O
sites O
for O
CCAAT B
- I
box I
binding I
factors I
are O
far O
upstream O
, O
embedded O
in O
a O
42 B
- I
nucleotide I
repeat I
element I
. O

TCF B
- I
1 I
alpha I
is O
currently O
unique O
among O
the O
newly O
emerging O
family O
of O
DNA B
- I
binding I
regulatory I
proteins I
that O
share O
the O
HMG B
motif I
in O
that O
it O
is O
a O
highly B
tissue I
- I
specific I
RNA I
polymerase I
II I
transcription B
factor I
. O

Moreover O
, O
kappa B
1 I
- I
kappa I
3 I
can O
each O
be O
deleted O
from O
the O
TNF B
- I
alpha I
promoter I
with O
little O
effect O
on O
the O
gene O
' O
s O
inducibility O
by O
PMA O
. O

Low O
levels O
of O
c B
- I
jun I
transcripts I
were O
detectable O
in O
resting O
human O
peripheral O
blood O
monocytes O
. O

In O
addition O
, O
cell B
- I
free I
synthesized I
hGR I
was O
capable O
of O
specific O
binding O
to O
glucocorticoid B
response I
element I
( I
GRE I
) I
- I
containing I
DNA I
fragments I
. O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B
2 I
fails O
to O
switch O
from O
Wp O
to O
Cp B
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp B
; O
( O
ii O
) O
a O
region O
from O
- B
429 I
to I
- I
245 I
base I
pairs I
upstream O
of O
Cp B
is O
essential O
for O
Cp B
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream B
and I
downstream I
sequences I
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B
2 I
- I
dependent I
enhancer I
; O
and O
( O
iv O
) O
DNase B
I I
protection O
employing O
nuclear O
extracts O
from O
B O
and O

T O
lymphocytes O
revealed O
a O
B B
- I
cell I
- I
specific I
footprint I
in O
the O
region O
of O
the O
EBNA B
2 I
- I
dependent I
enhancer I
. O

The O
rate O
of O
LTR B
- O
directed O
gene O
expression O
increased O
in O
response O
to O
treatment O
with O
either O
a O
phorbol O
ester O
or O
tumor B
necrosis I
factor I
alpha I
if O
either O
the O
NFAT B
- I
1 I
or O
NF B
kappa I
B I
binding I
sites I
were O
deleted O
, O
but O
failed O
to O
respond O
to O
these O
mitogenic O
stimuli O
if O
both O
sequences O
were O
absent O
. O

The O
induction O
of O
AP1 B
by O
okadaic O
acid O
suggests O
that O
protein B
phosphatases I
1 I
and I
2A I
( O
PP1 B
and O
PP2A B
) O
may O
be O
involved O
in O
T O
cell O
activation O
as O
important O
negative O
regulators O
of O
the O
transcription B
factor I
AP1 B
. O

Third O
, O
TCF B
- I
1 I
bound O
specifically O
to O
a O
functional O
T B
cell I
- I
specific I
element I
in O
the O
T B
cell I
receptor I
alpha I
( I
TCR I
- I
alpha I
) I
enhancer I
. O

When O
purified O
PRDII B
and I
tetrahexamer I
binding I
proteins I
were O
added O
to O
the O
induced O
extract O
, O
a O
4 O
- O
fold O
increase O
in O
transcription O
was O
observed O
. O

This O
was O
compared O
with O
the O
TREp B
binding O
of O
reticulocyte B
lysate I
- I
synthesized I
TRs I
. O

Functional O
analysis O
of O
cis B
- I
linked I
regulatory I
sequences I
in O
the O
HLA B
DRA I
promoter I
by O
transcription O
in O
vitro O
. O

We O
have O
carried O
out O
experiments O
to O
define O
the O
nature O
of O
the O
higher B
affinity I
CVZ I
binding I
site I
. O

When O
the O
human B
epsilon I
- I
or I
beta I
- I
globin I
genes I
driven O
by O
the O
dominant B
control I
region I
( O
DCR B
) O
are O
introduced O
into O
this O
system O
, O
the O
human B
epsilon I
- I
globin I
gene I
, O
in O
contrast O
to O
the O
beta B
- I
globin I
gene I
, O
is O
not O
deregulated O
by O
the O
presence O
of O
the O
DCR B
and O
is O
expressed O
strictly O
as O
an O
embryonic B
gene I
. O

Two O
distinct O
forms O
of O
active B
transcription I
factor I
CREB I
( O
cAMP B
response I
element I
binding I
protein I
) O
. O

Both O
proteins O
impart O
cAMP O
- O
regulated O
transcriptional O
activity O
to O
a O
heterologous B
DNA I
- I
binding I
domain I
, O
showing O
that O
cAMP O
directly O
modulates O
the O
transcriptional O
stimulatory O
activity O
of O
CREB B
. O

Competition O
experiments O
did O
not O
reveal O
any O
high B
- I
affinity I
binding I
site I
for O
BSAP B
in O
known O
regulatory B
regions I
of O
immunoglobulin B
and I
class I
II I
major I
histocompatibility I
( I
MHC I
) I
genes I
, O
suggesting O
that O
BSAP B
is O
a O
regulator O
of O
a O
different O
set O
of O
B B
- I
lymphoid I
- I
specific I
genes I
. O

The O
expression O
of O
the O
antibody B
- I
encoding I
genes I
, O
the O
immunoglobulin B
( I
Ig I
) I
genes I
, O
is O
also O
restricted O
to O
B O
cells O
. O

It O
appears O
that O
the O
B O
cell O
- O
specific O
expression O
of O
Ig B
genes I
is O
mediated O
at O
least O
in O
part O
by O
cell O
type B
- I
specific I
Oct I
factors I
, O
and O
that O
there O
are O
both O
quantitative O
and O
qualitative O
differences O
between O
Oct B
- I
1 I
and O
Oct B
- I
2 I
factors I
. O

However O
, O
despite O
its O
ability O
to O
activate O
transcription O
of O
a O
transfected B
reporter I
gene I
, O
the O
factor O
is O
apparently O
unable O
to O
bind O
to O
the O
endogenous B
Ig I
heavy I
chain I
enhancer I
in O
non O
- O
lymphoid O
cells O
: O
In O
previous O
experiments O
by O
others O
, O
the O
characteristic O
in O
vivo O
footprint O
of O
this O
factor O
, O
designated O
NF B
- I
muE3 I
, O
was O
detected O
in O
B O
cells O
but O
not O
in O
non O
- O
B O
cells O
. O

Induction O
of O
immediate B
early I
response I
genes I
by O
macrophage B
colony I
- I
stimulating I
factor I
in O
normal O
human O
monocytes O
. O

We O
have O
purified O
a O
new O
T B
- I
cell I
- I
specific I
factor I
, O
TCF B
- I
1 I
alpha I
, O
that O
is O
implicated O
in O
the O
activation O
of O
genes O
encoding O
a O
major O
component O
of O
the O
human B
T I
- I
cell I
receptor I
( O
TCR B
) O
. O

A O
powerful O
enhancer O
has O
been O
mapped O
to O
an O
18 B
- I
bp I
DNA I
segment I
located O
11 O
kb O
5 O
' O
to O
the O
human B
epsilon I
- I
globin I
gene I
within O
the O
dominant B
control I
or O
locus B
- I
activating I
region I
. O

A O
powerful O
enhancer O
has O
been O
mapped O
to O
an O
18 B
- I
bp I
DNA I
segment I
located O
11 O
kb O
5 O
' O
to O
the O
human B
epsilon I
- I
globin I
gene I
within O
the O
dominant B
control I
or O
locus B
- I
activating I
region I
. O

Two O
kappa B
B I
- I
like I
motifs I
at O
positions B
- I
98 I
to I
- I
108 I
of O
the O
GM B
- I
CSF I
promoter I
were O
also O
recognized O
but O
with O
much O
lower O
affinities O
. O

After O
in O
vitro O
adherence O
, O
human O
monocytes O
had O
a O
biphasic O
increase O
in O
PDGF B
( I
B I
) I
mRNA I
with O
peaks O
at O
6 O
h O
and O
13 O
d O
. O

This O
inducer O
can O
act O
in O
concert O
with O
the O
HIV B
- I
2 I
tat I
gene I
and O
T O
- O
cell O
activation O
in O
enhancing O
gene O
expression O
in O
human O
CD4 O
+ O
lymphocytes O
. O

Interaction O
of O
fibronectin B
with O
VLA B
- I
5 I
receptor I
on O
CD4 O
cells O
induces O
the O
AP B
- I
1 I
transcription I
factor I
. O

Suppression O
of O
signals O
required O
for O
activation O
of O
transcription B
factor I
NF I
- I
kappa I
B I
in O
cells O
constitutively O
expressing O
the O
HTLV B
- I
I I
Tax I
protein I
. O

Second O
, O
TRE B
- I
DNA I
binding I
proteins I
sedimented O
through O
a O
glycerol O
density O
gradient O
at O
rates O
corresponding O
to O
proteins O
of O
native O
molecular O
weights O
of O
35 O
to O
50 O
kD O
and O
110 O
kD O
. O

The O
cAMP B
- I
response I
element I
CRE B
, O
TGACGTCA O
, O
present O
in O
the O
21 B
base I
- I
pair I
sequence I
, O
appears O
to O
be O
essential O
for O
specific O
protein O
- O
TRE B
- O
DNA O
interactions O
because O
mutation O
of O
the O
two O
G O
' O
s O
destroys O
this O
complex O
. O

Activity O
of O
the O
immunoglobulin B
heavy I
and I
kappa I
light I
chain I
gene I
enhancers I
depends O
on O
a O
complex O
interplay O
of O
ubiquitous B
and I
developmentally I
regulated I
proteins I
. O

In O
lymphocytes O
, O
the O
octamer B
- I
binding I
protein I
Oct B
- I
2A I
and O
variants O
thereof O
are O
thought O
to O
contribute O
to O
the O
B B
- I
cell I
specific I
gene I
expression O
, O
while O
the O
ubiquitous O
protein O
Oct O
- O
1 O
seems O
to O
control O
general O
octamer B
site I
- O
dependent O
transcription O
. O

In O
the O
STLV O
- O
I O
- O
bearing O
T O
cell O
lines O
, O
tax1 B
- I
related I
antigen I
molecules I
detected O
by O
Lt B
- I
4 I
were O
heterogeneous O
, O
having O
molecular O
weights O
in O
the O
range O
of O
36 O
- O
41 O
kd O
. O

The O
corresponding O
region O
in O
the O
second O
AIDS O
retrovirus O
, O
HIV O
- O
2 O
, O
contains O
a O
conserved O
and O
a O
divergent O
NF B
kappa I
B I
binding I
site I
. O

A O
mutant B
LTR I
containing O
four O
base O
pair O
substitutions O
in O
the O
ets B
- I
1 I
binding I
site I
was O
constructed O
and O
was O
shown O
to O
have O
reduced O
binding O
in O
vitro O
. O

We O
propose O
that O
ets B
- I
1 I
functions O
as O
a O
transcriptional O
activator O
of O
mammalian O
type O
- O
C O
retroviruses O
and O
speculate O
that O
ets B
- I
related I
genes I
constitute O
a O
new O
group O
of O
eukaryotic B
DNA I
- I
binding I
proteins I
. O

Further O
, O
1 O
, O
25 O
( O
OH O
) O
2D3 O
inhibited O
the O
transcriptional O
activity O
of O
NF B
- I
kappa I
B I
in O
Jurkat O
cells O
transiently O
transfected O
with O
a O
construct B
containing O
four O
tandem B
repeats I
of O
the O
NF B
- I
kappa I
B I
binding I
sequence I
of O
the O
immunoglobulin B
kappa I
light I
chain I
gene I
linked O
to O
the O
chloramphenicol B
acetyltransferase I
reporter I
gene I
. O

The O
MZF B
- I
1 I
binding I
sites I
are O
present O
in O
the O
promoters B
of O
several O
genes B
expressed O
during O
myeloid O
differentiation O
, O
including O
the O
CD34 B
promoter I
. O

In O
contrast O
to O
hematopoietic O
cells O
, O
I O
kappa O
B O
alpha O
- O
/ O
- O
embryonic O
fibroblasts O
show O
minimal O
constitutive B
NF I
- I
kappa I
B I
, O
as O
well O
as O
normal O
signal O
- O
dependent O
NF B
- I
kappa I
B I
activation O
that O
is O
concomitant O
with O
I B
kappa I
B I
beta I
degradation O
. O

Here O
we O
show O
DNA O
damage O
- O
induced O
apoptosis O
in O
these O
T O
lymphocytes O
is O
dependent O
on O
the O
antioncogenic B
transcription I
factor I
interferon I
regulatory I
factor I
( B
IRF I
) I
- I
1 I
. O

Nonetheless O
, O
a O
membrane B
- I
proximal I
region I
of O
human O
IL B
- I
2R I
beta I
( O
Asn240 B
- I
Leu335 I
) O
was O
critical O
for O
JAK3 B
activation O
, O
and O
the O
amount O
of O
JAK3 B
present O
in O
activated O
IL B
- I
2 I
receptor I
complexes I
increased O
with O
time O
, O
suggesting O
that O
stabilization O
of O
JAK3 B
binding O
to O
the O
receptor B
complex I
relies O
on O
both O
IL B
- I
2R I
beta I
and O
IL B
- I
2R I
gamma I
. O

Sequence O
analysis O
of O
the O
5 B
' I
- I
flanking I
region I
of O
the O
CD69 B
gene I
revealed O
the O
presence O
of O
a O
potential O
TATA B
element I
30 B
base I
pairs I
upstream I
of O
the O
major O
transcription B
initiation I
site I
and O
several O
putative O
binding O
sequences O
for O
inducible O
transcription B
factors I
( O
NF B
- I
kappa I
B I
, O
Egr B
- I
1 I
, O
AP B
- I
1 I
) O
, O
which O
might O
mediate O
the O
inducible O
expression O
of O
this O
gene O
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

The O
exon B
- I
intron I
structure I
of O
the O
5 B
' I
portion I
of O
the O
thromboxane B
receptor I
gene I
was O
determined O
initially O
by O
comparing O
the O
nucleotide B
sequence I
of O
the O
5 B
' I
flanking I
genomic I
clone I
with O
that O
of O
a O
novel B
human I
uterine I
thromboxane I
receptor I
cDNA I
that O
extended O
the O
mRNA B
141 B
bp I
further I
upstream I
than O
the O
previously B
identified I
human I
placental I
cDNA I
. O

Inhibition O
of O
endogenous B
C I
/ I
EBP I
proteins I
, O
using O
either O
an O
excess O
of O
C B
/ I
EBP I
binding I
sites I
or O
a O
trans B
- I
dominant I
negative I
inhibitor I
, O
demonstrated O
that O
C B
/ I
EBP I
proteins I
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV B
- I
1 I
LTR I
transcription O
in O
the O
promonocytic O
cell O
line O
U937 O
. O

Inhibition O
of O
endogenous B
C I
/ I
EBP I
proteins I
, O
using O
either O
an O
excess O
of O
C B
/ I
EBP I
binding I
sites I
or O
a O
trans B
- I
dominant I
negative I
inhibitor I
, O
demonstrated O
that O
C B
/ I
EBP I
proteins I
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV B
- I
1 I
LTR I
transcription O
in O
the O
promonocytic O
cell O
line O
U937 O
. O

Inhibition O
of O
endogenous B
C I
/ I
EBP I
proteins I
, O
using O
either O
an O
excess O
of O
C B
/ I
EBP I
binding I
sites I
or O
a O
trans B
- I
dominant I
negative I
inhibitor I
, O
demonstrated O
that O
C B
/ I
EBP I
proteins I
are O
required O
for O
basal O
and O
activated O
levels O
of O
HIV B
- I
1 I
LTR I
transcription O
in O
the O
promonocytic O
cell O
line O
U937 O
. O

Northern O
( O
RNA O
) O
blots O
and O
binding O
assays O
showed O
that O
NF B
- I
IL6 I
is O
the O
only O
known O
C B
/ I
EBP I
family I
member I
which O
is O
increased O
when O
U937 O
cells O
are O
activated O
. O

However O
, O
transcription O
from O
crippled B
HIV I
- I
1 I
LTRs I
lacking O
C B
/ I
EBP I
sites I
can O
still O
be O
induced O
following O
activation O
of O
U937 O
cells O
. O

Increased O
intracellular O
stores O
of O
latent B
NF I
- I
kappa I
B I
may O
also O
result O
in O
rapid O
inducibility O
of O
NF B
- I
kappa I
B I
- O
dependent O
cytokine B
gene O
expression O
. O

In O
all O
cell O
lines O
investigated O
, O
the O
NF B
- I
kappa I
B I
complexes I
induced O
following O
CD30 B
engagement O
were O
shown O
to O
contain O
p50 B
NF I
- I
kappa I
B1 I
, O
p65 B
RelA I
, O
and O
possibly O
other O
transcription B
factors I
. O

In O
all O
cell O
lines O
investigated O
, O
the O
NF B
- I
kappa I
B I
complexes I
induced O
following O
CD30 B
engagement O
were O
shown O
to O
contain O
p50 B
NF I
- I
kappa I
B1 I
, O
p65 B
RelA I
, O
and O
possibly O
other O
transcription B
factors I
. O

Mutually O
exclusive O
interaction O
of O
a O
novel O
matrix B
attachment I
region I
binding I
protein I
and O
the O
NF B
- I
muNR I
enhancer I
repressor I
. O

Mutually O
exclusive O
interaction O
of O
a O
novel O
matrix B
attachment I
region I
binding I
protein I
and O
the O
NF B
- I
muNR I
enhancer I
repressor I
. O

We O
now O
show O
that O
the O
core O
contains O
a O
single O
critical O
c B
- I
Myb I
binding I
site I
. O

HIV B
- I
1 I
envelope I
glycoproteins I
induce O
activation O
of O
activated O
protein B
- I
1 I
in O
CD4 O
+ O
T O
cells O
[ O
published O
erratum O
appears O
in O
J O
Biol O
Chem O
1995 O
Dec O
1 O
; O
270 O
( O
48 O
) O
: O
29038 O
] O

